TY  - JOUR
AU  - Leković, Danijela
AU  - Bogdanović, Andrija
AU  - Sobas, Marta
AU  - Arsenović, Isidora
AU  - Smiljanić, Mihailo
AU  - Ivanović, Jelena
AU  - Bodrožić, Jelena
AU  - Čokić, Vladan
AU  - Milić, Nataša
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1344
AB  - Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (prePMF) initially have a similar phenotypic presentation with thrombocytosis. The aim of our study was to determine significant clinical-laboratory parameters at presentation to differentiate prePMF from ET as well as to develop and validate a predictive diagnostic prePMF model. This retrospective study included 464 patients divided into ET (289 pts) and prePMF (175 pts) groups. The model was built using data from a development cohort (229 pts; 143 ET, 86 prePMF), which was then tested in an internal validation cohort (235 pts; 146 ET, 89 prePMF). The most important prePMF predictors in the multivariate logistic model were age ≥ 60 years (RR = 2.2), splenomegaly (RR = 13.2), and increased lactat-dehidrogenase (RR = 2.8). Risk scores were assigned according to derived relative risk (RR) for age ≥ 60 years (1 point), splenomegaly (2 points), and increased lactat-dehidrogenase (1 point). Positive predictive value (PPV) for pre-PMF diagnosis with a score of ≥points was 69.8%, while for a score of ≥3 it was 88.2%. Diagnostic performance had similar values in the validation cohort. In MPN patients with thrombocytosis at presentation, the application of the new model enables differentiation of pre-PMF from ET, which is clinically relevant considering that these diseases have different prognoses and treatments.
PB  - Multidisciplinary Digital Publishing Institute (MDPI)
T2  - Cancers
T2  - Cancers
T1  - Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia
IS  - 16
SP  - 4180
VL  - 15
DO  - 10.3390/cancers15164180
ER  - 

@article{
author = "Leković, Danijela and Bogdanović, Andrija and Sobas, Marta and Arsenović, Isidora and Smiljanić, Mihailo and Ivanović, Jelena and Bodrožić, Jelena and Čokić, Vladan and Milić, Nataša",
year = "2023",
abstract = "Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (prePMF) initially have a similar phenotypic presentation with thrombocytosis. The aim of our study was to determine significant clinical-laboratory parameters at presentation to differentiate prePMF from ET as well as to develop and validate a predictive diagnostic prePMF model. This retrospective study included 464 patients divided into ET (289 pts) and prePMF (175 pts) groups. The model was built using data from a development cohort (229 pts; 143 ET, 86 prePMF), which was then tested in an internal validation cohort (235 pts; 146 ET, 89 prePMF). The most important prePMF predictors in the multivariate logistic model were age ≥ 60 years (RR = 2.2), splenomegaly (RR = 13.2), and increased lactat-dehidrogenase (RR = 2.8). Risk scores were assigned according to derived relative risk (RR) for age ≥ 60 years (1 point), splenomegaly (2 points), and increased lactat-dehidrogenase (1 point). Positive predictive value (PPV) for pre-PMF diagnosis with a score of ≥points was 69.8%, while for a score of ≥3 it was 88.2%. Diagnostic performance had similar values in the validation cohort. In MPN patients with thrombocytosis at presentation, the application of the new model enables differentiation of pre-PMF from ET, which is clinically relevant considering that these diseases have different prognoses and treatments.",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
journal = "Cancers, Cancers",
title = "Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia",
number = "16",
pages = "4180",
volume = "15",
doi = "10.3390/cancers15164180"
}

Leković, D., Bogdanović, A., Sobas, M., Arsenović, I., Smiljanić, M., Ivanović, J., Bodrožić, J., Čokić, V.,& Milić, N.. (2023). Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia. in Cancers
Multidisciplinary Digital Publishing Institute (MDPI)., 15(16), 4180.
https://doi.org/10.3390/cancers15164180

Leković D, Bogdanović A, Sobas M, Arsenović I, Smiljanić M, Ivanović J, Bodrožić J, Čokić V, Milić N. Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia. in Cancers. 2023;15(16):4180.
doi:10.3390/cancers15164180 .

Leković, Danijela, Bogdanović, Andrija, Sobas, Marta, Arsenović, Isidora, Smiljanić, Mihailo, Ivanović, Jelena, Bodrožić, Jelena, Čokić, Vladan, Milić, Nataša, "Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia" in Cancers, 15, no. 16 (2023):4180,
https://doi.org/10.3390/cancers15164180 . .

TY  - JOUR
AU  - Šefer, Dijana
AU  - Miljić, Predrag
AU  - Kraguljac-Kurtović, Nada
AU  - Bižić-Radulović, Sandra
AU  - Bogdanović, Andrija
AU  - Knežević, Vesna
AU  - Marković, Dragana
AU  - Beleslin-Čokić, Bojana
AU  - Novaković, Ivana
AU  - Marinković, Jelena
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Čokić, Vladan
PY  - 2022
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1231
AB  - Introduction: The impact of activated blood and endothelial cells on the thrombosis in myeloproliferative neoplasms (MPN) has not yet been clarified. We prospectively analyzed correlation between circulating leukocyte-platelet aggregates and soluble selectins to thrombosis occurrence in MPN, in the context of standard and cardiovascular risk factors, and different clinical and biological characteristics. Methods: Flow cytometric analysis of neutrophil-platelet (Neu-Plt) and monocyte-platelet (Mo-Plt) aggregates in peripheral blood, as well as quantification of soluble E-/L-/P-selectins by enzyme immunoassay, was performed on 95 newly diagnosed MPN patients. Results: During the follow-up, thrombosis occurred in 12.6% MPN patients (arterial 9.4%, venous 3.2%), with a mean time of 39 months. The overall incidence rate of main thrombotic events was 4.36 per 100 patient-years. The incidence of arterial hypertension (HTA) was significantly higher in patients with thrombosis, compared to those without thrombosis (P <.05). The level of soluble P-selectin was significantly higher in patients with thrombosis compared to those without thrombosis (346.89 ng/mL vs 286.39 ng/mL, P =.034). The mean level of Neu-Plt (26.7% vs 22.4%) and Mo-Plt (17.8% vs 12.3%) aggregates did not differ significantly between the groups with and without thrombosis. A multivariate COX proportional hazard regression model confirmed an independent predictive significance of Mo-Plt aggregates (HR = 1.561, 95% CI: 1.007-2.420, P =.046), as well as the cumulative effect of Mo-Plt aggregates and HTA (HR = 1.975, 95%CI: 1.215-3.212, P =.006) for thrombosis occurrence. Conclusion: Monocyte-platelet aggregates represent an independent risk factor for thrombosis occurrence, further on supported by HTA.
T2  - International Journal of Laboratory Hematology
T1  - Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms
EP  - 312
IS  - 2
SP  - 302
VL  - 44
DO  - 10.1111/ijlh.13754
ER  - 

@article{
author = "Šefer, Dijana and Miljić, Predrag and Kraguljac-Kurtović, Nada and Bižić-Radulović, Sandra and Bogdanović, Andrija and Knežević, Vesna and Marković, Dragana and Beleslin-Čokić, Bojana and Novaković, Ivana and Marinković, Jelena and Leković, Danijela and Gotić, Mirjana and Čokić, Vladan",
year = "2022",
abstract = "Introduction: The impact of activated blood and endothelial cells on the thrombosis in myeloproliferative neoplasms (MPN) has not yet been clarified. We prospectively analyzed correlation between circulating leukocyte-platelet aggregates and soluble selectins to thrombosis occurrence in MPN, in the context of standard and cardiovascular risk factors, and different clinical and biological characteristics. Methods: Flow cytometric analysis of neutrophil-platelet (Neu-Plt) and monocyte-platelet (Mo-Plt) aggregates in peripheral blood, as well as quantification of soluble E-/L-/P-selectins by enzyme immunoassay, was performed on 95 newly diagnosed MPN patients. Results: During the follow-up, thrombosis occurred in 12.6% MPN patients (arterial 9.4%, venous 3.2%), with a mean time of 39 months. The overall incidence rate of main thrombotic events was 4.36 per 100 patient-years. The incidence of arterial hypertension (HTA) was significantly higher in patients with thrombosis, compared to those without thrombosis (P <.05). The level of soluble P-selectin was significantly higher in patients with thrombosis compared to those without thrombosis (346.89 ng/mL vs 286.39 ng/mL, P =.034). The mean level of Neu-Plt (26.7% vs 22.4%) and Mo-Plt (17.8% vs 12.3%) aggregates did not differ significantly between the groups with and without thrombosis. A multivariate COX proportional hazard regression model confirmed an independent predictive significance of Mo-Plt aggregates (HR = 1.561, 95% CI: 1.007-2.420, P =.046), as well as the cumulative effect of Mo-Plt aggregates and HTA (HR = 1.975, 95%CI: 1.215-3.212, P =.006) for thrombosis occurrence. Conclusion: Monocyte-platelet aggregates represent an independent risk factor for thrombosis occurrence, further on supported by HTA.",
journal = "International Journal of Laboratory Hematology",
title = "Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms",
pages = "312-302",
number = "2",
volume = "44",
doi = "10.1111/ijlh.13754"
}

Šefer, D., Miljić, P., Kraguljac-Kurtović, N., Bižić-Radulović, S., Bogdanović, A., Knežević, V., Marković, D., Beleslin-Čokić, B., Novaković, I., Marinković, J., Leković, D., Gotić, M.,& Čokić, V.. (2022). Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms. in International Journal of Laboratory Hematology, 44(2), 302-312.
https://doi.org/10.1111/ijlh.13754

Šefer D, Miljić P, Kraguljac-Kurtović N, Bižić-Radulović S, Bogdanović A, Knežević V, Marković D, Beleslin-Čokić B, Novaković I, Marinković J, Leković D, Gotić M, Čokić V. Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms. in International Journal of Laboratory Hematology. 2022;44(2):302-312.
doi:10.1111/ijlh.13754 .

Šefer, Dijana, Miljić, Predrag, Kraguljac-Kurtović, Nada, Bižić-Radulović, Sandra, Bogdanović, Andrija, Knežević, Vesna, Marković, Dragana, Beleslin-Čokić, Bojana, Novaković, Ivana, Marinković, Jelena, Leković, Danijela, Gotić, Mirjana, Čokić, Vladan, "Correlation between leukocyte-platelet aggregates and thrombosis in myeloproliferative neoplasms" in International Journal of Laboratory Hematology, 44, no. 2 (2022):302-312,
https://doi.org/10.1111/ijlh.13754 . .

TY  - JOUR
AU  - Diklić, Miloš
AU  - Mitrović-Ajtić, Olivera
AU  - Subotički, Tijana
AU  - Đikić, Dragoslava
AU  - Kovačić, Marijana
AU  - Bjelica, Sunčica
AU  - Beleslin-Čokić, Bojana
AU  - Tošić, Milica
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Santibanez, Juan F.
AU  - Čokić, Vladan
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1024
AB  - This study has been performed to determine the mechanism of activation of the myeloid related S100A proteins by inflammatory cytokines in myeloproliferative neoplasm (MPN). Besides microarray analysis of MPN-derived CD34(+) cells, we analysed the pro-inflammatory IL6 and anti-inflammatory IL10 dependence of NF-kappa B, PI3K-AKT, and JAK-STAT signalling during induction of S100A proteins in mononuclear cells of MPN, by immunoblotting and flow cytometry. We observed the reduced gene expression linked to NF-kappa B and inflammation signalling in MPN-derived CD34(+) cells. Both IL6 and IL10 reduced S100A8 and 100A9 protein levels mediated via NF-kappa B and PI3K signalling, respectively, in mononuclear cells of essential thrombocythemia (ET). We also determined the increased percentage of S100A8 and S100A9 positive granulocytes in ET and primary myelofibrosis, upgraded by the JAK2V617F mutant allele burden. S100A8/9 heterodimer induced JAK1/2-dependent mitotic arrest of the ET-derived granulocytes. Significance of the study We demonstrated that inflammation reduced the myeloid related S100A8/9 proteins by negative feedback mechanism in ET. S100A8/9 can be a diagnostic marker of inflammation in MPN, supported by the concomitant NF-kappa B and JAK1/2 signalling inhibition in regulation of myeloproliferation and therapy of MPN.
PB  - Wiley, Hoboken
T2  - Cell Biochemistry & Function
T1  - IL6 inhibition of inflammatory S100A8/9 proteins is NF-kappa B mediated in essential thrombocythemia
EP  - 372
IS  - 4
SP  - 362
VL  - 38
DO  - 10.1002/cbf.3482
ER  - 

@article{
author = "Diklić, Miloš and Mitrović-Ajtić, Olivera and Subotički, Tijana and Đikić, Dragoslava and Kovačić, Marijana and Bjelica, Sunčica and Beleslin-Čokić, Bojana and Tošić, Milica and Leković, Danijela and Gotić, Mirjana and Santibanez, Juan F. and Čokić, Vladan",
year = "2020",
abstract = "This study has been performed to determine the mechanism of activation of the myeloid related S100A proteins by inflammatory cytokines in myeloproliferative neoplasm (MPN). Besides microarray analysis of MPN-derived CD34(+) cells, we analysed the pro-inflammatory IL6 and anti-inflammatory IL10 dependence of NF-kappa B, PI3K-AKT, and JAK-STAT signalling during induction of S100A proteins in mononuclear cells of MPN, by immunoblotting and flow cytometry. We observed the reduced gene expression linked to NF-kappa B and inflammation signalling in MPN-derived CD34(+) cells. Both IL6 and IL10 reduced S100A8 and 100A9 protein levels mediated via NF-kappa B and PI3K signalling, respectively, in mononuclear cells of essential thrombocythemia (ET). We also determined the increased percentage of S100A8 and S100A9 positive granulocytes in ET and primary myelofibrosis, upgraded by the JAK2V617F mutant allele burden. S100A8/9 heterodimer induced JAK1/2-dependent mitotic arrest of the ET-derived granulocytes. Significance of the study We demonstrated that inflammation reduced the myeloid related S100A8/9 proteins by negative feedback mechanism in ET. S100A8/9 can be a diagnostic marker of inflammation in MPN, supported by the concomitant NF-kappa B and JAK1/2 signalling inhibition in regulation of myeloproliferation and therapy of MPN.",
publisher = "Wiley, Hoboken",
journal = "Cell Biochemistry & Function",
title = "IL6 inhibition of inflammatory S100A8/9 proteins is NF-kappa B mediated in essential thrombocythemia",
pages = "372-362",
number = "4",
volume = "38",
doi = "10.1002/cbf.3482"
}

Diklić, M., Mitrović-Ajtić, O., Subotički, T., Đikić, D., Kovačić, M., Bjelica, S., Beleslin-Čokić, B., Tošić, M., Leković, D., Gotić, M., Santibanez, J. F.,& Čokić, V.. (2020). IL6 inhibition of inflammatory S100A8/9 proteins is NF-kappa B mediated in essential thrombocythemia. in Cell Biochemistry & Function
Wiley, Hoboken., 38(4), 362-372.
https://doi.org/10.1002/cbf.3482

Diklić M, Mitrović-Ajtić O, Subotički T, Đikić D, Kovačić M, Bjelica S, Beleslin-Čokić B, Tošić M, Leković D, Gotić M, Santibanez JF, Čokić V. IL6 inhibition of inflammatory S100A8/9 proteins is NF-kappa B mediated in essential thrombocythemia. in Cell Biochemistry & Function. 2020;38(4):362-372.
doi:10.1002/cbf.3482 .

Diklić, Miloš, Mitrović-Ajtić, Olivera, Subotički, Tijana, Đikić, Dragoslava, Kovačić, Marijana, Bjelica, Sunčica, Beleslin-Čokić, Bojana, Tošić, Milica, Leković, Danijela, Gotić, Mirjana, Santibanez, Juan F., Čokić, Vladan, "IL6 inhibition of inflammatory S100A8/9 proteins is NF-kappa B mediated in essential thrombocythemia" in Cell Biochemistry & Function, 38, no. 4 (2020):362-372,
https://doi.org/10.1002/cbf.3482 . .

TY  - JOUR
AU  - Nienhold, Ronny
AU  - Ashcroft, Peter
AU  - Zmajković, Jakub
AU  - Rai, Shivam
AU  - Rao, Tata Nageswara
AU  - Drexler, Beatrice
AU  - Meyer, Sara C.
AU  - Lundberg, Pontus
AU  - Passweg, Jakob R.
AU  - Leković, Danijela
AU  - Čokić, Vladan
AU  - Bonhoeffer, Sebastian
AU  - Skoda, Radek C.
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1012
PB  - Amer Soc Hematology, Washington
T2  - Blood
T1  - MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages
EP  - 2595
IS  - 22
SP  - 2591
VL  - 136
DO  - 10.1182/blood.2019002943
ER  - 

@article{
author = "Nienhold, Ronny and Ashcroft, Peter and Zmajković, Jakub and Rai, Shivam and Rao, Tata Nageswara and Drexler, Beatrice and Meyer, Sara C. and Lundberg, Pontus and Passweg, Jakob R. and Leković, Danijela and Čokić, Vladan and Bonhoeffer, Sebastian and Skoda, Radek C.",
year = "2020",
publisher = "Amer Soc Hematology, Washington",
journal = "Blood",
title = "MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages",
pages = "2595-2591",
number = "22",
volume = "136",
doi = "10.1182/blood.2019002943"
}

Nienhold, R., Ashcroft, P., Zmajković, J., Rai, S., Rao, T. N., Drexler, B., Meyer, S. C., Lundberg, P., Passweg, J. R., Leković, D., Čokić, V., Bonhoeffer, S.,& Skoda, R. C.. (2020). MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. in Blood
Amer Soc Hematology, Washington., 136(22), 2591-2595.
https://doi.org/10.1182/blood.2019002943

Nienhold R, Ashcroft P, Zmajković J, Rai S, Rao TN, Drexler B, Meyer SC, Lundberg P, Passweg JR, Leković D, Čokić V, Bonhoeffer S, Skoda RC. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. in Blood. 2020;136(22):2591-2595.
doi:10.1182/blood.2019002943 .

Nienhold, Ronny, Ashcroft, Peter, Zmajković, Jakub, Rai, Shivam, Rao, Tata Nageswara, Drexler, Beatrice, Meyer, Sara C., Lundberg, Pontus, Passweg, Jakob R., Leković, Danijela, Čokić, Vladan, Bonhoeffer, Sebastian, Skoda, Radek C., "MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages" in Blood, 136, no. 22 (2020):2591-2595,
https://doi.org/10.1182/blood.2019002943 . .

TY  - JOUR
AU  - Subotički, Tijana
AU  - Mitrović-Ajtić, Olivera
AU  - Beleslin-Čokić, Bojana
AU  - Bjelica, Sunčica
AU  - Đikić, Dragoslava
AU  - Diklić, Miloš
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Santibanez, Juan F.
AU  - Noguchi, Constance T.
AU  - Čokić, Vladan
PY  - 2019
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/952
AB  - Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolitinib. To explore the mechanism of ruxolitinib's limited effect, we examined the JAK1/2 mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory interleukin-6 (IL-6) in MPN granulocytes and JAK2V617F mutated human erythroleukemia (HEL) cells. We found that JAK1/2 or JAK2 inhibition prevented the IL-6 activation of STAT3 and AKT pathways in polycythemia vera and HEL cells. Further, we showed that these inhibitors also blocked the IL-6 activation of the AKT pathway in primary myelofibrosis (PMF). Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes. Regarding a cell cycle, we found that IL-6 reduction of HEL cells percentage in G2M phase was reversed by ruxolitinib (2.6 fold). Moreover, ruxolitinib potentiated apoptosis of PMF granulocytes (1.6 fold). Regarding DNA replication, we found that ruxolitinib prevented the IL-6 augmentation of MPN granulocytes frequency in the S phase of the cell cycle (up to 2.9 fold). The inflammatory stimulation induces a cross-talk between the proliferation linked pathways, where JAK1/2 inhibition is compensated by the activation of the ERK1/2 pathway during IL-6 stimulation of DNA replication.
PB  - Wiley, Hoboken
T2  - Cell Biology International
T1  - IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling
EP  - 206
IS  - 2
SP  - 192
VL  - 43
DO  - 10.1002/cbin.11084
ER  - 

@article{
author = "Subotički, Tijana and Mitrović-Ajtić, Olivera and Beleslin-Čokić, Bojana and Bjelica, Sunčica and Đikić, Dragoslava and Diklić, Miloš and Leković, Danijela and Gotić, Mirjana and Santibanez, Juan F. and Noguchi, Constance T. and Čokić, Vladan",
year = "2019",
abstract = "Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolitinib. To explore the mechanism of ruxolitinib's limited effect, we examined the JAK1/2 mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory interleukin-6 (IL-6) in MPN granulocytes and JAK2V617F mutated human erythroleukemia (HEL) cells. We found that JAK1/2 or JAK2 inhibition prevented the IL-6 activation of STAT3 and AKT pathways in polycythemia vera and HEL cells. Further, we showed that these inhibitors also blocked the IL-6 activation of the AKT pathway in primary myelofibrosis (PMF). Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes. Regarding a cell cycle, we found that IL-6 reduction of HEL cells percentage in G2M phase was reversed by ruxolitinib (2.6 fold). Moreover, ruxolitinib potentiated apoptosis of PMF granulocytes (1.6 fold). Regarding DNA replication, we found that ruxolitinib prevented the IL-6 augmentation of MPN granulocytes frequency in the S phase of the cell cycle (up to 2.9 fold). The inflammatory stimulation induces a cross-talk between the proliferation linked pathways, where JAK1/2 inhibition is compensated by the activation of the ERK1/2 pathway during IL-6 stimulation of DNA replication.",
publisher = "Wiley, Hoboken",
journal = "Cell Biology International",
title = "IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling",
pages = "206-192",
number = "2",
volume = "43",
doi = "10.1002/cbin.11084"
}

Subotički, T., Mitrović-Ajtić, O., Beleslin-Čokić, B., Bjelica, S., Đikić, D., Diklić, M., Leković, D., Gotić, M., Santibanez, J. F., Noguchi, C. T.,& Čokić, V.. (2019). IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling. in Cell Biology International
Wiley, Hoboken., 43(2), 192-206.
https://doi.org/10.1002/cbin.11084

Subotički T, Mitrović-Ajtić O, Beleslin-Čokić B, Bjelica S, Đikić D, Diklić M, Leković D, Gotić M, Santibanez JF, Noguchi CT, Čokić V. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling. in Cell Biology International. 2019;43(2):192-206.
doi:10.1002/cbin.11084 .

Subotički, Tijana, Mitrović-Ajtić, Olivera, Beleslin-Čokić, Bojana, Bjelica, Sunčica, Đikić, Dragoslava, Diklić, Miloš, Leković, Danijela, Gotić, Mirjana, Santibanez, Juan F., Noguchi, Constance T., Čokić, Vladan, "IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling" in Cell Biology International, 43, no. 2 (2019):192-206,
https://doi.org/10.1002/cbin.11084 . .

TY  - JOUR
AU  - Rao, Tata Nageswara
AU  - Hansen, Nils
AU  - Hilfiker, Julian
AU  - Rai, Shivam
AU  - Majewska, Julia-Magdalena
AU  - Leković, Danijela
AU  - Gezer, Deniz
AU  - Andina, Nicola
AU  - Galli, Serena
AU  - Cassel, Teresa
AU  - Geier, Florian
AU  - Delezie, Julien
AU  - Nienhold, Ronny
AU  - Hao-Shen, Hui
AU  - Beisel, Christian
AU  - Di Palma, Serena
AU  - Dimeloe, Sarah
AU  - Trebicka, Jonel
AU  - Wolf, Dominik
AU  - Gassmann, Max
AU  - Fan, Teresa W. -M.
AU  - Lane, Andrew N.
AU  - Handschin, Christoph
AU  - Dirnhofer, Stefan
AU  - Kroeger, Nicolaus
AU  - Hess, Christoph
AU  - Radimerski, Thomas
AU  - Koschmieder, Steffen
AU  - Čokić, Vladan
AU  - Skoda, Radek C.
PY  - 2019
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/919
AB  - Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells. We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative neoplasms (MPNs). We found that expression of mutant JAK2 augmented and subverted metabolic activity of MPN cells, resulting in systemic metabolic changes in vivo, including hypoglycemia, adipose tissue atrophy, and early mortality. Hypoglycemia in MPN mouse models correlated with hyperactive erythropoiesis and was due to a combination of elevated glycolysis and increased oxidative phosphorylation. Modulating nutrient supply through high-fat diet improved survival, whereas high-glucose diet augmented the MPN phenotype. Transcriptomic and metabolomic analyses identified numerous metabolic nodes in JAK2-mutant hematopoietic stem and progenitor cells that were altered in comparison with wild-type controls. We studied the consequences of elevated levels of Pfkfb3, a key regulatory enzyme of glycolysis, and found that pharmacological inhibition of Pfkfb3 with the small molecule 3PO reversed hypoglycemia and reduced hematopoietic manifestations of MPNs. These effects were additive with the JAK1/2 inhibitor ruxolitinib in vivo and in vitro. Inhibition of glycolysis by 3PO altered the redox homeostasis, leading to accumulation of reactive oxygen species and augmented apoptosis rate. Our findings reveal the contribution of metabolic alterations to the pathogenesis of MPNs and suggest that metabolic dependencies of mutant cells represent vulnerabilities that can be targeted for treating MPNs.
PB  - Amer Soc Hematology, Washington
T2  - Blood
T1  - JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
EP  - 1846
IS  - 21
SP  - 1832
VL  - 134
DO  - 10.1182/blood.2019000162
ER  - 

@article{
author = "Rao, Tata Nageswara and Hansen, Nils and Hilfiker, Julian and Rai, Shivam and Majewska, Julia-Magdalena and Leković, Danijela and Gezer, Deniz and Andina, Nicola and Galli, Serena and Cassel, Teresa and Geier, Florian and Delezie, Julien and Nienhold, Ronny and Hao-Shen, Hui and Beisel, Christian and Di Palma, Serena and Dimeloe, Sarah and Trebicka, Jonel and Wolf, Dominik and Gassmann, Max and Fan, Teresa W. -M. and Lane, Andrew N. and Handschin, Christoph and Dirnhofer, Stefan and Kroeger, Nicolaus and Hess, Christoph and Radimerski, Thomas and Koschmieder, Steffen and Čokić, Vladan and Skoda, Radek C.",
year = "2019",
abstract = "Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells. We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative neoplasms (MPNs). We found that expression of mutant JAK2 augmented and subverted metabolic activity of MPN cells, resulting in systemic metabolic changes in vivo, including hypoglycemia, adipose tissue atrophy, and early mortality. Hypoglycemia in MPN mouse models correlated with hyperactive erythropoiesis and was due to a combination of elevated glycolysis and increased oxidative phosphorylation. Modulating nutrient supply through high-fat diet improved survival, whereas high-glucose diet augmented the MPN phenotype. Transcriptomic and metabolomic analyses identified numerous metabolic nodes in JAK2-mutant hematopoietic stem and progenitor cells that were altered in comparison with wild-type controls. We studied the consequences of elevated levels of Pfkfb3, a key regulatory enzyme of glycolysis, and found that pharmacological inhibition of Pfkfb3 with the small molecule 3PO reversed hypoglycemia and reduced hematopoietic manifestations of MPNs. These effects were additive with the JAK1/2 inhibitor ruxolitinib in vivo and in vitro. Inhibition of glycolysis by 3PO altered the redox homeostasis, leading to accumulation of reactive oxygen species and augmented apoptosis rate. Our findings reveal the contribution of metabolic alterations to the pathogenesis of MPNs and suggest that metabolic dependencies of mutant cells represent vulnerabilities that can be targeted for treating MPNs.",
publisher = "Amer Soc Hematology, Washington",
journal = "Blood",
title = "JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms",
pages = "1846-1832",
number = "21",
volume = "134",
doi = "10.1182/blood.2019000162"
}

Rao, T. N., Hansen, N., Hilfiker, J., Rai, S., Majewska, J., Leković, D., Gezer, D., Andina, N., Galli, S., Cassel, T., Geier, F., Delezie, J., Nienhold, R., Hao-Shen, H., Beisel, C., Di Palma, S., Dimeloe, S., Trebicka, J., Wolf, D., Gassmann, M., Fan, T. W. -M., Lane, A. N., Handschin, C., Dirnhofer, S., Kroeger, N., Hess, C., Radimerski, T., Koschmieder, S., Čokić, V.,& Skoda, R. C.. (2019). JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. in Blood
Amer Soc Hematology, Washington., 134(21), 1832-1846.
https://doi.org/10.1182/blood.2019000162

Rao TN, Hansen N, Hilfiker J, Rai S, Majewska J, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW-, Lane AN, Handschin C, Dirnhofer S, Kroeger N, Hess C, Radimerski T, Koschmieder S, Čokić V, Skoda RC. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. in Blood. 2019;134(21):1832-1846.
doi:10.1182/blood.2019000162 .

Rao, Tata Nageswara, Hansen, Nils, Hilfiker, Julian, Rai, Shivam, Majewska, Julia-Magdalena, Leković, Danijela, Gezer, Deniz, Andina, Nicola, Galli, Serena, Cassel, Teresa, Geier, Florian, Delezie, Julien, Nienhold, Ronny, Hao-Shen, Hui, Beisel, Christian, Di Palma, Serena, Dimeloe, Sarah, Trebicka, Jonel, Wolf, Dominik, Gassmann, Max, Fan, Teresa W. -M., Lane, Andrew N., Handschin, Christoph, Dirnhofer, Stefan, Kroeger, Nicolaus, Hess, Christoph, Radimerski, Thomas, Koschmieder, Steffen, Čokić, Vladan, Skoda, Radek C., "JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms" in Blood, 134, no. 21 (2019):1832-1846,
https://doi.org/10.1182/blood.2019000162 . .

TY  - JOUR
AU  - Kovačić, Marijana
AU  - Mitrović-Ajtić, Olivera
AU  - Beleslin-Čokić, Bojana
AU  - Đikić, Dragoslava
AU  - Subotički, Tijana
AU  - Diklić, Miloš
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Mossuz, Pascal
AU  - Čokić, Vladan
PY  - 2018
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/834
AB  - Purpose Previously, the family of S 100A proteins has been found to be associated with inflammation and myelopoiesis and to be able to induce or support myeloproliferation during chronic inflammation. Here, we studied the inflammatory myeloid-related proteins Si 00A4, S 100A8, S 100A9 and S100Al2 in myeloproliferative neoplasms (MPNs) in order to assess the involvement of chronic inflammation in the pathogenesis of MPN. Methods We analyzed the S100A4, S100A8, S100A9 and S100Al2 mRNA and protein levels in the bone marrow and circulation of 140 patients with MPN and 15 healthy controls using Western blotting, microarray-based mRNA expression profiling and ELISA assays, respectively. In addition we performed functional studies on the proliferation-related AKT and ERK1/2 signaling pathways in MPN-derived granulocytes using Western blotting and proteomic analyses. Results We found that the S100A mRNA levels were increased in MPN patient-derived circulatory CD34(+ )cells, and that their protein expression levels were also augmented in their granulocytes and bone marrow stroma cells, depending on the JAK2V617F mutation allele burden. We also found that calreticulin (CALR) mutations were related to reduced S100A8 plasma levels in primary myelofibrosis (PMF). The S100A8 plasma levels were found to be increased in MPN, the S100A9 plasma levels in PMF and essential thrombocythemia (ET), and the S100A12 plasma levels in polycythemia vera (PV). These 5100A plasma levels showed a positive correlation with the systemic inflammation marker IL-8, as well as with the numbers of leukocytes and thrombocytes, depending on the JAK2V617F mutation status. Additionally, we found that heterodimeric S100A8/9 can inhibit the AKT pathway in MPN-derived granulocytes mediated by the Toll-like receptor 4 (TLR4), depending on the CALR mutation status. Conversely, we found that blocking of the receptor for advanced glycation end products (RAGE) increased the S100A8/9-mediated inhibition of AKT signaling in the MPN-derived granulocytes. Moreover, we found that heterodimeric S100A8/9 generally induced TLR4-mediated ERK1/2 dephosphorylation proportionally to the JAK2V617F mutation allele burden. TLR4/RAGE blocking prevented the S100A8/9-mediated inhibition of ERK1/2 phosphorylation in PV. Conclusions From our data we conclude that the 5100A8 and S100A9 granulocyte and plasma levels are increased in MPN patients, along with inflammation markers, depending on their JAK2V617F mutation allele burden. We also found that SIO0A8/9-mediated inhibition of the proliferation-related AKT and ERK1/2 signaling pathways can be decreased by CALR mutationdependent TLR4 blocking and increased by RAGE inhibition in MPN.
PB  - Springer, Dordrecht
T2  - Cellular Oncology
T1  - TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms
EP  - 553
IS  - 5
SP  - 541
VL  - 41
DO  - 10.1007/s13402-018-0392-6
ER  - 

@article{
author = "Kovačić, Marijana and Mitrović-Ajtić, Olivera and Beleslin-Čokić, Bojana and Đikić, Dragoslava and Subotički, Tijana and Diklić, Miloš and Leković, Danijela and Gotić, Mirjana and Mossuz, Pascal and Čokić, Vladan",
year = "2018",
abstract = "Purpose Previously, the family of S 100A proteins has been found to be associated with inflammation and myelopoiesis and to be able to induce or support myeloproliferation during chronic inflammation. Here, we studied the inflammatory myeloid-related proteins Si 00A4, S 100A8, S 100A9 and S100Al2 in myeloproliferative neoplasms (MPNs) in order to assess the involvement of chronic inflammation in the pathogenesis of MPN. Methods We analyzed the S100A4, S100A8, S100A9 and S100Al2 mRNA and protein levels in the bone marrow and circulation of 140 patients with MPN and 15 healthy controls using Western blotting, microarray-based mRNA expression profiling and ELISA assays, respectively. In addition we performed functional studies on the proliferation-related AKT and ERK1/2 signaling pathways in MPN-derived granulocytes using Western blotting and proteomic analyses. Results We found that the S100A mRNA levels were increased in MPN patient-derived circulatory CD34(+ )cells, and that their protein expression levels were also augmented in their granulocytes and bone marrow stroma cells, depending on the JAK2V617F mutation allele burden. We also found that calreticulin (CALR) mutations were related to reduced S100A8 plasma levels in primary myelofibrosis (PMF). The S100A8 plasma levels were found to be increased in MPN, the S100A9 plasma levels in PMF and essential thrombocythemia (ET), and the S100A12 plasma levels in polycythemia vera (PV). These 5100A plasma levels showed a positive correlation with the systemic inflammation marker IL-8, as well as with the numbers of leukocytes and thrombocytes, depending on the JAK2V617F mutation status. Additionally, we found that heterodimeric S100A8/9 can inhibit the AKT pathway in MPN-derived granulocytes mediated by the Toll-like receptor 4 (TLR4), depending on the CALR mutation status. Conversely, we found that blocking of the receptor for advanced glycation end products (RAGE) increased the S100A8/9-mediated inhibition of AKT signaling in the MPN-derived granulocytes. Moreover, we found that heterodimeric S100A8/9 generally induced TLR4-mediated ERK1/2 dephosphorylation proportionally to the JAK2V617F mutation allele burden. TLR4/RAGE blocking prevented the S100A8/9-mediated inhibition of ERK1/2 phosphorylation in PV. Conclusions From our data we conclude that the 5100A8 and S100A9 granulocyte and plasma levels are increased in MPN patients, along with inflammation markers, depending on their JAK2V617F mutation allele burden. We also found that SIO0A8/9-mediated inhibition of the proliferation-related AKT and ERK1/2 signaling pathways can be decreased by CALR mutationdependent TLR4 blocking and increased by RAGE inhibition in MPN.",
publisher = "Springer, Dordrecht",
journal = "Cellular Oncology",
title = "TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms",
pages = "553-541",
number = "5",
volume = "41",
doi = "10.1007/s13402-018-0392-6"
}

Kovačić, M., Mitrović-Ajtić, O., Beleslin-Čokić, B., Đikić, D., Subotički, T., Diklić, M., Leković, D., Gotić, M., Mossuz, P.,& Čokić, V.. (2018). TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms. in Cellular Oncology
Springer, Dordrecht., 41(5), 541-553.
https://doi.org/10.1007/s13402-018-0392-6

Kovačić M, Mitrović-Ajtić O, Beleslin-Čokić B, Đikić D, Subotički T, Diklić M, Leković D, Gotić M, Mossuz P, Čokić V. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms. in Cellular Oncology. 2018;41(5):541-553.
doi:10.1007/s13402-018-0392-6 .

Kovačić, Marijana, Mitrović-Ajtić, Olivera, Beleslin-Čokić, Bojana, Đikić, Dragoslava, Subotički, Tijana, Diklić, Miloš, Leković, Danijela, Gotić, Mirjana, Mossuz, Pascal, Čokić, Vladan, "TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms" in Cellular Oncology, 41, no. 5 (2018):541-553,
https://doi.org/10.1007/s13402-018-0392-6 . .

TY  - JOUR
AU  - Subotički, Tijana
AU  - Mitrović-Ajtić, Olivera
AU  - Mićić, Mileva
AU  - Kravic-Stevović, Tamara
AU  - Đikić, Dragoslava
AU  - Diklić, Miloš
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Čokić, Vladan
PY  - 2018
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/853
AB  - In accordance with increased proliferation in myeloproliferative neoplasm (MPN), the goal is to evaluate the immunoexpression of: beta-catenin, PPAR-gamma and Ki67 protein, to compare them with bone marrow ultrastructural characteristics in patients with MPN. Immunoexpression and electron microscopy of bone marrow was analyzed in 30 Ph-negative MPN patients, including per 10 patients with polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The quantity of beta-catenin immunoreactive cells was significantly higher in PV then in ET (p  lt  0.01) or PMF group of patients (p  lt  0.01) and also in ET versus PMF group of patients (p  lt  0.01). Erythroid lineage showed absent beta-catenin staining without immunoreactivity in nucleus. In contrast, immunoreactivity for PPAR-gamma was localized mostly in megakaryocytes and the highest number of PPAR-gamma immunopositive cells was detected in PMF group of patients. In addition, the proliferative Ki67 index was significantly increased in the PMF and PV patients compared to patients with ET. Also, the megakaryocytes showed abnormal maturation in PMF group of patients as determined by ultrastructural analysis. These results indicated that PV dominantly expressed beta-catenin and proliferation marker Ki67 in bone marrow, while PMF is linked preferentially to PPAR-gamma immunopositive megakaryocytes characterized by abnormal maturation.
PB  - Taylor & Francis Inc, Philadelphia
T2  - Ultrastructural Pathology
T1  - beta-catenin and PPAR-gamma levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study
EP  - 507
IS  - 6
SP  - 498
VL  - 42
DO  - 10.1080/01913123.2018.1558323
ER  - 

@article{
author = "Subotički, Tijana and Mitrović-Ajtić, Olivera and Mićić, Mileva and Kravic-Stevović, Tamara and Đikić, Dragoslava and Diklić, Miloš and Leković, Danijela and Gotić, Mirjana and Čokić, Vladan",
year = "2018",
abstract = "In accordance with increased proliferation in myeloproliferative neoplasm (MPN), the goal is to evaluate the immunoexpression of: beta-catenin, PPAR-gamma and Ki67 protein, to compare them with bone marrow ultrastructural characteristics in patients with MPN. Immunoexpression and electron microscopy of bone marrow was analyzed in 30 Ph-negative MPN patients, including per 10 patients with polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The quantity of beta-catenin immunoreactive cells was significantly higher in PV then in ET (p  lt  0.01) or PMF group of patients (p  lt  0.01) and also in ET versus PMF group of patients (p  lt  0.01). Erythroid lineage showed absent beta-catenin staining without immunoreactivity in nucleus. In contrast, immunoreactivity for PPAR-gamma was localized mostly in megakaryocytes and the highest number of PPAR-gamma immunopositive cells was detected in PMF group of patients. In addition, the proliferative Ki67 index was significantly increased in the PMF and PV patients compared to patients with ET. Also, the megakaryocytes showed abnormal maturation in PMF group of patients as determined by ultrastructural analysis. These results indicated that PV dominantly expressed beta-catenin and proliferation marker Ki67 in bone marrow, while PMF is linked preferentially to PPAR-gamma immunopositive megakaryocytes characterized by abnormal maturation.",
publisher = "Taylor & Francis Inc, Philadelphia",
journal = "Ultrastructural Pathology",
title = "beta-catenin and PPAR-gamma levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study",
pages = "507-498",
number = "6",
volume = "42",
doi = "10.1080/01913123.2018.1558323"
}

Subotički, T., Mitrović-Ajtić, O., Mićić, M., Kravic-Stevović, T., Đikić, D., Diklić, M., Leković, D., Gotić, M.,& Čokić, V.. (2018). beta-catenin and PPAR-gamma levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study. in Ultrastructural Pathology
Taylor & Francis Inc, Philadelphia., 42(6), 498-507.
https://doi.org/10.1080/01913123.2018.1558323

Subotički T, Mitrović-Ajtić O, Mićić M, Kravic-Stevović T, Đikić D, Diklić M, Leković D, Gotić M, Čokić V. beta-catenin and PPAR-gamma levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study. in Ultrastructural Pathology. 2018;42(6):498-507.
doi:10.1080/01913123.2018.1558323 .

Subotički, Tijana, Mitrović-Ajtić, Olivera, Mićić, Mileva, Kravic-Stevović, Tamara, Đikić, Dragoslava, Diklić, Miloš, Leković, Danijela, Gotić, Mirjana, Čokić, Vladan, "beta-catenin and PPAR-gamma levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study" in Ultrastructural Pathology, 42, no. 6 (2018):498-507,
https://doi.org/10.1080/01913123.2018.1558323 . .

TY  - CONF
AU  - Kovačić, Marijana
AU  - Mitrović-Ajtić, Olivera
AU  - Beleslin-Čokić, Bojana
AU  - Diklić, Miloš
AU  - Subotički, Tijana
AU  - Đikić, Dragoslava
AU  - Momčilović, Sanja
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Čokić, Vladan
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/780
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - S100a8/9 activation of mapk pathway is supported by its receptors rage and tlr4 in polycythemia vera
EP  - 540
SP  - 540
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_rimi_780
ER  - 

@conference{
author = "Kovačić, Marijana and Mitrović-Ajtić, Olivera and Beleslin-Čokić, Bojana and Diklić, Miloš and Subotički, Tijana and Đikić, Dragoslava and Momčilović, Sanja and Leković, Danijela and Gotić, Mirjana and Čokić, Vladan",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "S100a8/9 activation of mapk pathway is supported by its receptors rage and tlr4 in polycythemia vera",
pages = "540-540",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_rimi_780"
}

Kovačić, M., Mitrović-Ajtić, O., Beleslin-Čokić, B., Diklić, M., Subotički, T., Đikić, D., Momčilović, S., Leković, D., Gotić, M.,& Čokić, V.. (2017). S100a8/9 activation of mapk pathway is supported by its receptors rage and tlr4 in polycythemia vera. in Haematologica
Ferrata Storti Foundation, Pavia., 102, 540-540.
https://hdl.handle.net/21.15107/rcub_rimi_780

Kovačić M, Mitrović-Ajtić O, Beleslin-Čokić B, Diklić M, Subotički T, Đikić D, Momčilović S, Leković D, Gotić M, Čokić V. S100a8/9 activation of mapk pathway is supported by its receptors rage and tlr4 in polycythemia vera. in Haematologica. 2017;102:540-540.
https://hdl.handle.net/21.15107/rcub_rimi_780 .

Kovačić, Marijana, Mitrović-Ajtić, Olivera, Beleslin-Čokić, Bojana, Diklić, Miloš, Subotički, Tijana, Đikić, Dragoslava, Momčilović, Sanja, Leković, Danijela, Gotić, Mirjana, Čokić, Vladan, "S100a8/9 activation of mapk pathway is supported by its receptors rage and tlr4 in polycythemia vera" in Haematologica, 102 (2017):540-540,
https://hdl.handle.net/21.15107/rcub_rimi_780 .

TY  - JOUR
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Skoda, Radek C.
AU  - Beleslin-Čokić, Bojana
AU  - Milić, Nataša
AU  - Mitrović-Ajtić, Olivera
AU  - Nienhold, Ronny
AU  - Sefer, Dijana
AU  - Subotički, Tijana
AU  - Kovačić, Marijana
AU  - Marković, Dragana
AU  - Diklić, Miloš
AU  - Čokić, Vladan
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/804
AB  - Increased angiogenesis in BCR-ABL1 negative myeloproliferative neoplasms (MPNs) has been recognized, but its connection with clinical and molecular markers needs to be defined. The aims of study were to (1) assess bone marrow (BM) angiogenesis measured by microvessel density (MVD) using CD34 and CD105 antibodies; (2) analyze correlation of MVD with plasma angiogenic factors including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8; (3) examine the association of MVD with clinicopathological and molecular markers. We examined 90 de novo MPN patients (30 polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET)) and 10 age-matched controls. MVD was analyzed by immunohistochemistry "hot spot" method, angiogenic factors by immunoassay and JAK2V617F, and CALR mutations by DNA sequencing and allelic PCR. MVD was significantly increased in MPNs compared to controls (PMF  gt  PV  gt  ET). Correlation between MVD and plasma angiogenic factors was found in MPNs. MVD was significantly increased in patients with JAK2V617F mutation and correlated with JAK2 mutant allele burden (CD34-MVD: rho = 0.491, p  lt  0.001; CD105-MVD: rho = 0.276, p = 0.02) but not with CALR mutation. MVD correlated with leukocyte count, serum lactate dehydrogenase, hepatomegaly, and splenomegaly. BM fibrosis was significantly associated with CD34-MVD, CD105-MVD, interleukin-8, and JAK2 mutant allele burden. JAK2 homozygote status had positive predictive value (100%) for BM fibrosis. Patients with prefibrotic PMF had significantly higher MVD than patients with ET, and we could recommend MVD to be additional histopathological marker to distinguish these two entities. This study also highlights the strong correlation of MVD with plasma angiogenic factors, JAK2 mutant allele burden, and BM fibrosis in MPNs.
PB  - Springer, New York
T2  - Annals of Hematology
T1  - Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations
EP  - 404
IS  - 3
SP  - 393
VL  - 96
DO  - 10.1007/s00277-016-2890-9
ER  - 

@article{
author = "Leković, Danijela and Gotić, Mirjana and Skoda, Radek C. and Beleslin-Čokić, Bojana and Milić, Nataša and Mitrović-Ajtić, Olivera and Nienhold, Ronny and Sefer, Dijana and Subotički, Tijana and Kovačić, Marijana and Marković, Dragana and Diklić, Miloš and Čokić, Vladan",
year = "2017",
abstract = "Increased angiogenesis in BCR-ABL1 negative myeloproliferative neoplasms (MPNs) has been recognized, but its connection with clinical and molecular markers needs to be defined. The aims of study were to (1) assess bone marrow (BM) angiogenesis measured by microvessel density (MVD) using CD34 and CD105 antibodies; (2) analyze correlation of MVD with plasma angiogenic factors including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8; (3) examine the association of MVD with clinicopathological and molecular markers. We examined 90 de novo MPN patients (30 polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET)) and 10 age-matched controls. MVD was analyzed by immunohistochemistry "hot spot" method, angiogenic factors by immunoassay and JAK2V617F, and CALR mutations by DNA sequencing and allelic PCR. MVD was significantly increased in MPNs compared to controls (PMF  gt  PV  gt  ET). Correlation between MVD and plasma angiogenic factors was found in MPNs. MVD was significantly increased in patients with JAK2V617F mutation and correlated with JAK2 mutant allele burden (CD34-MVD: rho = 0.491, p  lt  0.001; CD105-MVD: rho = 0.276, p = 0.02) but not with CALR mutation. MVD correlated with leukocyte count, serum lactate dehydrogenase, hepatomegaly, and splenomegaly. BM fibrosis was significantly associated with CD34-MVD, CD105-MVD, interleukin-8, and JAK2 mutant allele burden. JAK2 homozygote status had positive predictive value (100%) for BM fibrosis. Patients with prefibrotic PMF had significantly higher MVD than patients with ET, and we could recommend MVD to be additional histopathological marker to distinguish these two entities. This study also highlights the strong correlation of MVD with plasma angiogenic factors, JAK2 mutant allele burden, and BM fibrosis in MPNs.",
publisher = "Springer, New York",
journal = "Annals of Hematology",
title = "Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations",
pages = "404-393",
number = "3",
volume = "96",
doi = "10.1007/s00277-016-2890-9"
}

Leković, D., Gotić, M., Skoda, R. C., Beleslin-Čokić, B., Milić, N., Mitrović-Ajtić, O., Nienhold, R., Sefer, D., Subotički, T., Kovačić, M., Marković, D., Diklić, M.,& Čokić, V.. (2017). Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. in Annals of Hematology
Springer, New York., 96(3), 393-404.
https://doi.org/10.1007/s00277-016-2890-9

Leković D, Gotić M, Skoda RC, Beleslin-Čokić B, Milić N, Mitrović-Ajtić O, Nienhold R, Sefer D, Subotički T, Kovačić M, Marković D, Diklić M, Čokić V. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. in Annals of Hematology. 2017;96(3):393-404.
doi:10.1007/s00277-016-2890-9 .

Leković, Danijela, Gotić, Mirjana, Skoda, Radek C., Beleslin-Čokić, Bojana, Milić, Nataša, Mitrović-Ajtić, Olivera, Nienhold, Ronny, Sefer, Dijana, Subotički, Tijana, Kovačić, Marijana, Marković, Dragana, Diklić, Miloš, Čokić, Vladan, "Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations" in Annals of Hematology, 96, no. 3 (2017):393-404,
https://doi.org/10.1007/s00277-016-2890-9 . .

TY  - JOUR
AU  - Subotički, Tijana
AU  - Mitrović-Ajtić, Olivera
AU  - Beleslin-Čokić, Bojana
AU  - Nienhold, Ronny
AU  - Diklić, Miloš
AU  - Đikić, Dragoslava
AU  - Leković, Danijela
AU  - Bulat, Tanja
AU  - Marković, Dragana
AU  - Gotić, Mirjana
AU  - Noguchi, Constance T.
AU  - Schechter, Alan N.
AU  - Skoda, Radek C.
AU  - Čokić, Vladan
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/807
AB  - It has been shown that angiogenesis and inflammation play an important role in development of most hematological malignancies including the myeloproliferative neoplasm (MPN). The aim of this study was to investigate and correlate the levels of key angiogenic molecules such as hypoxia-inducible factor-1 (HIF-1), vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) in peripheral blood and bone marrow cells of MPN patients, along with JAK2V617F mutation allele burden and effects of therapy. HIF-1 and VEGF gene expression were decreased, while eNOS mRNA levels were increased in granulocytes of MPN patients. Furthermore, positively correlated and increased VEGF and eNOS protein levels were in negative correlation with HIF-1 levels in granulocytes of MPN patients. According to immunoblotting, the generally augmented angiogenic factors demonstrated JAK2V617F allele burden dependence only in granulocytes of PMF. The angiogenic factors were largely reduced after hydroxyurea therapy in granulocytes of MPN patients. Levels of eNOS protein expression were stimulated by Calreticulin mutations in granulocytes of essential thrombocythemia. Immunocytochemical analyses of CD34(+) cells showed a more pronounced enhancement of angiogenic factors than in granulocytes. Increased gene expression linked to the proinflammatory TGF and MAPK signaling pathways were detected in CD34(+) cells of MPN patients. In conclusion, the angiogenesis is increased in several cell types of MPN patients supported by the transcriptional activation of inflammation-related target genes, and is not limited to bone marrow stroma cells. It also appears that some of the benefit of hydroxyurea therapy of the MPN is mediated by effects on angiogenic factors.
PB  - Wiley-Blackwell, Hoboken
T2  - Molecular Carcinogenesis
T1  - Angiogenic factors are increased in circulating granulocytes and CD34(+) cells of myeloproliferative neoplasms
EP  - 579
IS  - 2
SP  - 567
VL  - 56
DO  - 10.1002/mc.22517
ER  - 

@article{
author = "Subotički, Tijana and Mitrović-Ajtić, Olivera and Beleslin-Čokić, Bojana and Nienhold, Ronny and Diklić, Miloš and Đikić, Dragoslava and Leković, Danijela and Bulat, Tanja and Marković, Dragana and Gotić, Mirjana and Noguchi, Constance T. and Schechter, Alan N. and Skoda, Radek C. and Čokić, Vladan",
year = "2017",
abstract = "It has been shown that angiogenesis and inflammation play an important role in development of most hematological malignancies including the myeloproliferative neoplasm (MPN). The aim of this study was to investigate and correlate the levels of key angiogenic molecules such as hypoxia-inducible factor-1 (HIF-1), vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) in peripheral blood and bone marrow cells of MPN patients, along with JAK2V617F mutation allele burden and effects of therapy. HIF-1 and VEGF gene expression were decreased, while eNOS mRNA levels were increased in granulocytes of MPN patients. Furthermore, positively correlated and increased VEGF and eNOS protein levels were in negative correlation with HIF-1 levels in granulocytes of MPN patients. According to immunoblotting, the generally augmented angiogenic factors demonstrated JAK2V617F allele burden dependence only in granulocytes of PMF. The angiogenic factors were largely reduced after hydroxyurea therapy in granulocytes of MPN patients. Levels of eNOS protein expression were stimulated by Calreticulin mutations in granulocytes of essential thrombocythemia. Immunocytochemical analyses of CD34(+) cells showed a more pronounced enhancement of angiogenic factors than in granulocytes. Increased gene expression linked to the proinflammatory TGF and MAPK signaling pathways were detected in CD34(+) cells of MPN patients. In conclusion, the angiogenesis is increased in several cell types of MPN patients supported by the transcriptional activation of inflammation-related target genes, and is not limited to bone marrow stroma cells. It also appears that some of the benefit of hydroxyurea therapy of the MPN is mediated by effects on angiogenic factors.",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Molecular Carcinogenesis",
title = "Angiogenic factors are increased in circulating granulocytes and CD34(+) cells of myeloproliferative neoplasms",
pages = "579-567",
number = "2",
volume = "56",
doi = "10.1002/mc.22517"
}

Subotički, T., Mitrović-Ajtić, O., Beleslin-Čokić, B., Nienhold, R., Diklić, M., Đikić, D., Leković, D., Bulat, T., Marković, D., Gotić, M., Noguchi, C. T., Schechter, A. N., Skoda, R. C.,& Čokić, V.. (2017). Angiogenic factors are increased in circulating granulocytes and CD34(+) cells of myeloproliferative neoplasms. in Molecular Carcinogenesis
Wiley-Blackwell, Hoboken., 56(2), 567-579.
https://doi.org/10.1002/mc.22517

Subotički T, Mitrović-Ajtić O, Beleslin-Čokić B, Nienhold R, Diklić M, Đikić D, Leković D, Bulat T, Marković D, Gotić M, Noguchi CT, Schechter AN, Skoda RC, Čokić V. Angiogenic factors are increased in circulating granulocytes and CD34(+) cells of myeloproliferative neoplasms. in Molecular Carcinogenesis. 2017;56(2):567-579.
doi:10.1002/mc.22517 .

Subotički, Tijana, Mitrović-Ajtić, Olivera, Beleslin-Čokić, Bojana, Nienhold, Ronny, Diklić, Miloš, Đikić, Dragoslava, Leković, Danijela, Bulat, Tanja, Marković, Dragana, Gotić, Mirjana, Noguchi, Constance T., Schechter, Alan N., Skoda, Radek C., Čokić, Vladan, "Angiogenic factors are increased in circulating granulocytes and CD34(+) cells of myeloproliferative neoplasms" in Molecular Carcinogenesis, 56, no. 2 (2017):567-579,
https://doi.org/10.1002/mc.22517 . .

TY  - CONF
AU  - Subotički, Tijana
AU  - Beleslin-Čokić, Bojana
AU  - Leković, Danijela
AU  - Mojsilović, S.
AU  - Mitrović-Ajtić, Olivera
AU  - Kovačić, Marijana
AU  - Diklić, Miloš
AU  - Gotić, Mirjana
AU  - Čokić, Vladan
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/817
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Proinflammatory cytokine il-6 stimulation of angiogenic factors and DNA replication is blocked by jak-stat pathway inhibition in myeloproliferative neoplasms
EP  - 541
SP  - 540
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_rimi_817
ER  - 

@conference{
author = "Subotički, Tijana and Beleslin-Čokić, Bojana and Leković, Danijela and Mojsilović, S. and Mitrović-Ajtić, Olivera and Kovačić, Marijana and Diklić, Miloš and Gotić, Mirjana and Čokić, Vladan",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Proinflammatory cytokine il-6 stimulation of angiogenic factors and DNA replication is blocked by jak-stat pathway inhibition in myeloproliferative neoplasms",
pages = "541-540",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_rimi_817"
}

Subotički, T., Beleslin-Čokić, B., Leković, D., Mojsilović, S., Mitrović-Ajtić, O., Kovačić, M., Diklić, M., Gotić, M.,& Čokić, V.. (2017). Proinflammatory cytokine il-6 stimulation of angiogenic factors and DNA replication is blocked by jak-stat pathway inhibition in myeloproliferative neoplasms. in Haematologica
Ferrata Storti Foundation, Pavia., 102, 540-541.
https://hdl.handle.net/21.15107/rcub_rimi_817

Subotički T, Beleslin-Čokić B, Leković D, Mojsilović S, Mitrović-Ajtić O, Kovačić M, Diklić M, Gotić M, Čokić V. Proinflammatory cytokine il-6 stimulation of angiogenic factors and DNA replication is blocked by jak-stat pathway inhibition in myeloproliferative neoplasms. in Haematologica. 2017;102:540-541.
https://hdl.handle.net/21.15107/rcub_rimi_817 .

Subotički, Tijana, Beleslin-Čokić, Bojana, Leković, Danijela, Mojsilović, S., Mitrović-Ajtić, Olivera, Kovačić, Marijana, Diklić, Miloš, Gotić, Mirjana, Čokić, Vladan, "Proinflammatory cytokine il-6 stimulation of angiogenic factors and DNA replication is blocked by jak-stat pathway inhibition in myeloproliferative neoplasms" in Haematologica, 102 (2017):540-541,
https://hdl.handle.net/21.15107/rcub_rimi_817 .

TY  - JOUR
AU  - Šefer, Dijana
AU  - Bižić-Radulović, Sandra
AU  - Kraguljac-Kurtović, Nada
AU  - Bogdanović, Andrija
AU  - Čokić, Vladan
AU  - Miljić, Predrag
AU  - Beleslin-Čokić, Bojana
AU  - Knežević, Vesna
AU  - Mitrović-Ajtić, Olivera
AU  - Leković, Danijela
AU  - Gotić, Mirjana
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/795
AB  - Introduction: Philadelphia-negative myeloproliferative neoplasms (Ph-MPN) are characterized by overproduction of one or more blood cell lines. Methods: We studied the proliferative characteristics of 91 patients with de novo Ph-MPN. Colony-forming cells (CFC) and endogenous colonies (EC), from bone marrow (BM) and/or peripheral blood (PB), were analyzed by colony assay based on methylcellulose. The level of circulating CD34(+) cells was determined by flow cytometry. Results: The total number of PB CFC in primary myelofibrosis (PMF) was increased compared to the control sample (P  lt  0.01) and essential thrombocythemia (ET) (P  lt  0.05). The highest number of BM and PB EC was observed in polycythemia vera (PV) (P  lt  0.01). Increased levels of CD34(+) cells characterized early-prefibrotic (57%) and advanced-fibrotic PMF (90%) as compared to PV (34%) and ET (32%) (P  lt  0.01). In the whole Ph-MPN group, the total number of PB CFC (P  lt  0.01), PB EC (P  lt  0.05), and CD34+ cells (P  lt  0.01) correlated with the degree of BM fibrosis. Higher levels of circulating CD34(+) cells in PMF correlated with the total number of PB EC (P  lt  0.05) and degree of BM fibrosis (P  lt  0.01). Conclusions: Exploration of the PB proliferative characteristics of Ph-MPN on diagnosis may be helpful in revealing early-prefibrotic PMF. Monitoring the levels of circulating CD34(+) cells may provide a sensitive indicator of fibrotic evolution in PV and PMF.
PB  - Wiley, Hoboken
T2  - International Journal of Laboratory Hematology
T1  - Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications
EP  - 31
IS  - 1
SP  - 21
VL  - 39
DO  - 10.1111/ijlh.12564
ER  - 

@article{
author = "Šefer, Dijana and Bižić-Radulović, Sandra and Kraguljac-Kurtović, Nada and Bogdanović, Andrija and Čokić, Vladan and Miljić, Predrag and Beleslin-Čokić, Bojana and Knežević, Vesna and Mitrović-Ajtić, Olivera and Leković, Danijela and Gotić, Mirjana",
year = "2017",
abstract = "Introduction: Philadelphia-negative myeloproliferative neoplasms (Ph-MPN) are characterized by overproduction of one or more blood cell lines. Methods: We studied the proliferative characteristics of 91 patients with de novo Ph-MPN. Colony-forming cells (CFC) and endogenous colonies (EC), from bone marrow (BM) and/or peripheral blood (PB), were analyzed by colony assay based on methylcellulose. The level of circulating CD34(+) cells was determined by flow cytometry. Results: The total number of PB CFC in primary myelofibrosis (PMF) was increased compared to the control sample (P  lt  0.01) and essential thrombocythemia (ET) (P  lt  0.05). The highest number of BM and PB EC was observed in polycythemia vera (PV) (P  lt  0.01). Increased levels of CD34(+) cells characterized early-prefibrotic (57%) and advanced-fibrotic PMF (90%) as compared to PV (34%) and ET (32%) (P  lt  0.01). In the whole Ph-MPN group, the total number of PB CFC (P  lt  0.01), PB EC (P  lt  0.05), and CD34+ cells (P  lt  0.01) correlated with the degree of BM fibrosis. Higher levels of circulating CD34(+) cells in PMF correlated with the total number of PB EC (P  lt  0.05) and degree of BM fibrosis (P  lt  0.01). Conclusions: Exploration of the PB proliferative characteristics of Ph-MPN on diagnosis may be helpful in revealing early-prefibrotic PMF. Monitoring the levels of circulating CD34(+) cells may provide a sensitive indicator of fibrotic evolution in PV and PMF.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Laboratory Hematology",
title = "Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications",
pages = "31-21",
number = "1",
volume = "39",
doi = "10.1111/ijlh.12564"
}

Šefer, D., Bižić-Radulović, S., Kraguljac-Kurtović, N., Bogdanović, A., Čokić, V., Miljić, P., Beleslin-Čokić, B., Knežević, V., Mitrović-Ajtić, O., Leković, D.,& Gotić, M.. (2017). Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. in International Journal of Laboratory Hematology
Wiley, Hoboken., 39(1), 21-31.
https://doi.org/10.1111/ijlh.12564

Šefer D, Bižić-Radulović S, Kraguljac-Kurtović N, Bogdanović A, Čokić V, Miljić P, Beleslin-Čokić B, Knežević V, Mitrović-Ajtić O, Leković D, Gotić M. Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. in International Journal of Laboratory Hematology. 2017;39(1):21-31.
doi:10.1111/ijlh.12564 .

Šefer, Dijana, Bižić-Radulović, Sandra, Kraguljac-Kurtović, Nada, Bogdanović, Andrija, Čokić, Vladan, Miljić, Predrag, Beleslin-Čokić, Bojana, Knežević, Vesna, Mitrović-Ajtić, Olivera, Leković, Danijela, Gotić, Mirjana, "Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications" in International Journal of Laboratory Hematology, 39, no. 1 (2017):21-31,
https://doi.org/10.1111/ijlh.12564 . .

TY  - CONF
AU  - Sefer, Dijana
AU  - Miljić, Predrag
AU  - Kraguljac-Kurtović, Nada
AU  - Bizic-Radulović, S.
AU  - Čokić, Vladan
AU  - Bogdanović, Andrija
AU  - Marković, Dragana
AU  - Knežević, V.
AU  - Leković, Danijela
AU  - Gotić, Mirjana
PY  - 2017
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/811
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Monitoring of leukocyte-platelet aggregates and selectin levels in patients with philadelphia-negative myeloproliferative neoplasms
EP  - 546
SP  - 545
VL  - 102
UR  - https://hdl.handle.net/21.15107/rcub_rimi_811
ER  - 

@conference{
author = "Sefer, Dijana and Miljić, Predrag and Kraguljac-Kurtović, Nada and Bizic-Radulović, S. and Čokić, Vladan and Bogdanović, Andrija and Marković, Dragana and Knežević, V. and Leković, Danijela and Gotić, Mirjana",
year = "2017",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Monitoring of leukocyte-platelet aggregates and selectin levels in patients with philadelphia-negative myeloproliferative neoplasms",
pages = "546-545",
volume = "102",
url = "https://hdl.handle.net/21.15107/rcub_rimi_811"
}

Sefer, D., Miljić, P., Kraguljac-Kurtović, N., Bizic-Radulović, S., Čokić, V., Bogdanović, A., Marković, D., Knežević, V., Leković, D.,& Gotić, M.. (2017). Monitoring of leukocyte-platelet aggregates and selectin levels in patients with philadelphia-negative myeloproliferative neoplasms. in Haematologica
Ferrata Storti Foundation, Pavia., 102, 545-546.
https://hdl.handle.net/21.15107/rcub_rimi_811

Sefer D, Miljić P, Kraguljac-Kurtović N, Bizic-Radulović S, Čokić V, Bogdanović A, Marković D, Knežević V, Leković D, Gotić M. Monitoring of leukocyte-platelet aggregates and selectin levels in patients with philadelphia-negative myeloproliferative neoplasms. in Haematologica. 2017;102:545-546.
https://hdl.handle.net/21.15107/rcub_rimi_811 .

Sefer, Dijana, Miljić, Predrag, Kraguljac-Kurtović, Nada, Bizic-Radulović, S., Čokić, Vladan, Bogdanović, Andrija, Marković, Dragana, Knežević, V., Leković, Danijela, Gotić, Mirjana, "Monitoring of leukocyte-platelet aggregates and selectin levels in patients with philadelphia-negative myeloproliferative neoplasms" in Haematologica, 102 (2017):545-546,
https://hdl.handle.net/21.15107/rcub_rimi_811 .

TY  - CONF
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Sefer, Dijana
AU  - Beleslin-Čokić, Bojana
AU  - Milić, Nataša
AU  - Mitrović-Ajtić, Olivera
AU  - Subotički, Tijana
AU  - Marković, Dragana
AU  - Buac, M.
AU  - Diklić, Miloš
AU  - Colović, N.
AU  - Bodrozić, J.
AU  - Čokić, Vladan
PY  - 2016
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/749
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Bone marrow microvessel density and plasma angiogenic factors in BCR-ABL1 negative myeloproliferative neoplasms: a study of 90 patients with clinicopathological and molecular correlations
EP  - 268
SP  - 267
VL  - 101
UR  - https://hdl.handle.net/21.15107/rcub_rimi_749
ER  - 

@conference{
author = "Leković, Danijela and Gotić, Mirjana and Sefer, Dijana and Beleslin-Čokić, Bojana and Milić, Nataša and Mitrović-Ajtić, Olivera and Subotički, Tijana and Marković, Dragana and Buac, M. and Diklić, Miloš and Colović, N. and Bodrozić, J. and Čokić, Vladan",
year = "2016",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Bone marrow microvessel density and plasma angiogenic factors in BCR-ABL1 negative myeloproliferative neoplasms: a study of 90 patients with clinicopathological and molecular correlations",
pages = "268-267",
volume = "101",
url = "https://hdl.handle.net/21.15107/rcub_rimi_749"
}

Leković, D., Gotić, M., Sefer, D., Beleslin-Čokić, B., Milić, N., Mitrović-Ajtić, O., Subotički, T., Marković, D., Buac, M., Diklić, M., Colović, N., Bodrozić, J.,& Čokić, V.. (2016). Bone marrow microvessel density and plasma angiogenic factors in BCR-ABL1 negative myeloproliferative neoplasms: a study of 90 patients with clinicopathological and molecular correlations. in Haematologica
Ferrata Storti Foundation, Pavia., 101, 267-268.
https://hdl.handle.net/21.15107/rcub_rimi_749

Leković D, Gotić M, Sefer D, Beleslin-Čokić B, Milić N, Mitrović-Ajtić O, Subotički T, Marković D, Buac M, Diklić M, Colović N, Bodrozić J, Čokić V. Bone marrow microvessel density and plasma angiogenic factors in BCR-ABL1 negative myeloproliferative neoplasms: a study of 90 patients with clinicopathological and molecular correlations. in Haematologica. 2016;101:267-268.
https://hdl.handle.net/21.15107/rcub_rimi_749 .

Leković, Danijela, Gotić, Mirjana, Sefer, Dijana, Beleslin-Čokić, Bojana, Milić, Nataša, Mitrović-Ajtić, Olivera, Subotički, Tijana, Marković, Dragana, Buac, M., Diklić, Miloš, Colović, N., Bodrozić, J., Čokić, Vladan, "Bone marrow microvessel density and plasma angiogenic factors in BCR-ABL1 negative myeloproliferative neoplasms: a study of 90 patients with clinicopathological and molecular correlations" in Haematologica, 101 (2016):267-268,
https://hdl.handle.net/21.15107/rcub_rimi_749 .

TY  - CONF
AU  - Sefer, Dijana
AU  - Miljić, Predrag
AU  - Kraguljac-Kurtović, Nada
AU  - Bizic-Radulović, S.
AU  - Čokić, Vladan
AU  - Marković, Dragana
AU  - Beleslin-Čokić, Bojana
AU  - Novaković, I.
AU  - Erić-Marinković, Jelena
AU  - Leković, Danijela
AU  - Bodrozić, J.
AU  - Gotić, Mirjana
PY  - 2016
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/750
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Predictive role of circulating leucocyte-platelet aggregates for thromboembolic complications in philadelphia-negative myeloproliferative neoplasms: a prospective study
EP  - 266
SP  - 266
VL  - 101
UR  - https://hdl.handle.net/21.15107/rcub_rimi_750
ER  - 

@conference{
author = "Sefer, Dijana and Miljić, Predrag and Kraguljac-Kurtović, Nada and Bizic-Radulović, S. and Čokić, Vladan and Marković, Dragana and Beleslin-Čokić, Bojana and Novaković, I. and Erić-Marinković, Jelena and Leković, Danijela and Bodrozić, J. and Gotić, Mirjana",
year = "2016",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Predictive role of circulating leucocyte-platelet aggregates for thromboembolic complications in philadelphia-negative myeloproliferative neoplasms: a prospective study",
pages = "266-266",
volume = "101",
url = "https://hdl.handle.net/21.15107/rcub_rimi_750"
}

Sefer, D., Miljić, P., Kraguljac-Kurtović, N., Bizic-Radulović, S., Čokić, V., Marković, D., Beleslin-Čokić, B., Novaković, I., Erić-Marinković, J., Leković, D., Bodrozić, J.,& Gotić, M.. (2016). Predictive role of circulating leucocyte-platelet aggregates for thromboembolic complications in philadelphia-negative myeloproliferative neoplasms: a prospective study. in Haematologica
Ferrata Storti Foundation, Pavia., 101, 266-266.
https://hdl.handle.net/21.15107/rcub_rimi_750

Sefer D, Miljić P, Kraguljac-Kurtović N, Bizic-Radulović S, Čokić V, Marković D, Beleslin-Čokić B, Novaković I, Erić-Marinković J, Leković D, Bodrozić J, Gotić M. Predictive role of circulating leucocyte-platelet aggregates for thromboembolic complications in philadelphia-negative myeloproliferative neoplasms: a prospective study. in Haematologica. 2016;101:266-266.
https://hdl.handle.net/21.15107/rcub_rimi_750 .

Sefer, Dijana, Miljić, Predrag, Kraguljac-Kurtović, Nada, Bizic-Radulović, S., Čokić, Vladan, Marković, Dragana, Beleslin-Čokić, Bojana, Novaković, I., Erić-Marinković, Jelena, Leković, Danijela, Bodrozić, J., Gotić, Mirjana, "Predictive role of circulating leucocyte-platelet aggregates for thromboembolic complications in philadelphia-negative myeloproliferative neoplasms: a prospective study" in Haematologica, 101 (2016):266-266,
https://hdl.handle.net/21.15107/rcub_rimi_750 .

TY  - CONF
AU  - Čokić, Vladan
AU  - Mossuz, Pascal
AU  - Puri, Raj K.
AU  - Beleslin-Čokić, Bojana
AU  - Mitrović-Ajtić, Olivera
AU  - Subotički, Tijana
AU  - Diklić, Miloš
AU  - Leković, Danijela
AU  - Gotić, Mirjana
PY  - 2015
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/616
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Gene and protein expression analyses of the mtor signaling pathway in myeloproliferative neoplasms
EP  - 528
SP  - 528
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_rimi_616
ER  - 

@conference{
author = "Čokić, Vladan and Mossuz, Pascal and Puri, Raj K. and Beleslin-Čokić, Bojana and Mitrović-Ajtić, Olivera and Subotički, Tijana and Diklić, Miloš and Leković, Danijela and Gotić, Mirjana",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Gene and protein expression analyses of the mtor signaling pathway in myeloproliferative neoplasms",
pages = "528-528",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_rimi_616"
}

Čokić, V., Mossuz, P., Puri, R. K., Beleslin-Čokić, B., Mitrović-Ajtić, O., Subotički, T., Diklić, M., Leković, D.,& Gotić, M.. (2015). Gene and protein expression analyses of the mtor signaling pathway in myeloproliferative neoplasms. in Haematologica
Ferrata Storti Foundation, Pavia., 100, 528-528.
https://hdl.handle.net/21.15107/rcub_rimi_616

Čokić V, Mossuz P, Puri RK, Beleslin-Čokić B, Mitrović-Ajtić O, Subotički T, Diklić M, Leković D, Gotić M. Gene and protein expression analyses of the mtor signaling pathway in myeloproliferative neoplasms. in Haematologica. 2015;100:528-528.
https://hdl.handle.net/21.15107/rcub_rimi_616 .

Čokić, Vladan, Mossuz, Pascal, Puri, Raj K., Beleslin-Čokić, Bojana, Mitrović-Ajtić, Olivera, Subotički, Tijana, Diklić, Miloš, Leković, Danijela, Gotić, Mirjana, "Gene and protein expression analyses of the mtor signaling pathway in myeloproliferative neoplasms" in Haematologica, 100 (2015):528-528,
https://hdl.handle.net/21.15107/rcub_rimi_616 .

TY  - JOUR
AU  - Čokić, Vladan
AU  - Mossuz, Pascal
AU  - Han, Jing
AU  - Socoro, Nuria
AU  - Beleslin-Čokić, Bojana
AU  - Mitrović, Olivera
AU  - Subotički, Tijana
AU  - Diklić, Miloš
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Puri, Raj K.
AU  - Noguchi, Constance T.
AU  - Schechter, Alan N.
PY  - 2015
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/670
AB  - The gene and protein expression profiles in myeloproliferative neoplasms (MPNs) may reveal gene and protein markers of a potential clinical relevance in diagnosis, treatment and prediction of response to therapy. Using cDNA microarray analysis of 25,100 unique genes, we studied the gene expression profile of CD34(+) cells and granulocytes obtained from peripheral blood of subjects with essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). The microarray analyses of the CD34(+) cells and granulocytes were performed from 20 de novo MPN subjects: JAK2 positive ET, PV, PMF subjects, and JAK2 negative ET/PMF subjects. The granulocytes for proteomic studies were pooled in 4 groups: PV with JAK2 mutant allele burden above 80%, ET with JAK2 mutation, PMF with JAK2 mutation and ET/PMF with no JAK2 mutation. The number of differentially regulated genes was about two fold larger in CD34(+) cells compared to granulocytes. Thirty-six genes (including RUNX1, TNFRSF19) were persistently highly expressed, while 42 genes (including FOXD4, PDE4A) were underexpressed both in CD34(+) cells and granulocytes. Using proteomic studies, significant up-regulation was observed for MAPK and PI3K/AKT signaling regulators that control myeloid cell apoptosis and proliferation: RAC2, MNDA, S100A8/9, CORO1A, and GNAI2. When the status of the mTOR signaling pathway related genes was analyzed, PI3K/AKT regulators were preferentially up-regulated in CD34(+) cells of MPNs, with down-regulated major components of the protein complex EIF4F. Molecular profiling of CD34(+) cells and granulocytes of MPN determined gene expression patterns beyond their recognized function in disease pathogenesis that included dominant up-regulation of PI3K/AKT signaling.
PB  - Public Library Science, San Francisco
T2  - PLoS One
T1  - Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway
IS  - 8
VL  - 10
DO  - 10.1371/journal.pone.0135463
ER  - 

@article{
author = "Čokić, Vladan and Mossuz, Pascal and Han, Jing and Socoro, Nuria and Beleslin-Čokić, Bojana and Mitrović, Olivera and Subotički, Tijana and Diklić, Miloš and Leković, Danijela and Gotić, Mirjana and Puri, Raj K. and Noguchi, Constance T. and Schechter, Alan N.",
year = "2015",
abstract = "The gene and protein expression profiles in myeloproliferative neoplasms (MPNs) may reveal gene and protein markers of a potential clinical relevance in diagnosis, treatment and prediction of response to therapy. Using cDNA microarray analysis of 25,100 unique genes, we studied the gene expression profile of CD34(+) cells and granulocytes obtained from peripheral blood of subjects with essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). The microarray analyses of the CD34(+) cells and granulocytes were performed from 20 de novo MPN subjects: JAK2 positive ET, PV, PMF subjects, and JAK2 negative ET/PMF subjects. The granulocytes for proteomic studies were pooled in 4 groups: PV with JAK2 mutant allele burden above 80%, ET with JAK2 mutation, PMF with JAK2 mutation and ET/PMF with no JAK2 mutation. The number of differentially regulated genes was about two fold larger in CD34(+) cells compared to granulocytes. Thirty-six genes (including RUNX1, TNFRSF19) were persistently highly expressed, while 42 genes (including FOXD4, PDE4A) were underexpressed both in CD34(+) cells and granulocytes. Using proteomic studies, significant up-regulation was observed for MAPK and PI3K/AKT signaling regulators that control myeloid cell apoptosis and proliferation: RAC2, MNDA, S100A8/9, CORO1A, and GNAI2. When the status of the mTOR signaling pathway related genes was analyzed, PI3K/AKT regulators were preferentially up-regulated in CD34(+) cells of MPNs, with down-regulated major components of the protein complex EIF4F. Molecular profiling of CD34(+) cells and granulocytes of MPN determined gene expression patterns beyond their recognized function in disease pathogenesis that included dominant up-regulation of PI3K/AKT signaling.",
publisher = "Public Library Science, San Francisco",
journal = "PLoS One",
title = "Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway",
number = "8",
volume = "10",
doi = "10.1371/journal.pone.0135463"
}

Čokić, V., Mossuz, P., Han, J., Socoro, N., Beleslin-Čokić, B., Mitrović, O., Subotički, T., Diklić, M., Leković, D., Gotić, M., Puri, R. K., Noguchi, C. T.,& Schechter, A. N.. (2015). Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. in PLoS One
Public Library Science, San Francisco., 10(8).
https://doi.org/10.1371/journal.pone.0135463

Čokić V, Mossuz P, Han J, Socoro N, Beleslin-Čokić B, Mitrović O, Subotički T, Diklić M, Leković D, Gotić M, Puri RK, Noguchi CT, Schechter AN. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. in PLoS One. 2015;10(8).
doi:10.1371/journal.pone.0135463 .

Čokić, Vladan, Mossuz, Pascal, Han, Jing, Socoro, Nuria, Beleslin-Čokić, Bojana, Mitrović, Olivera, Subotički, Tijana, Diklić, Miloš, Leković, Danijela, Gotić, Mirjana, Puri, Raj K., Noguchi, Constance T., Schechter, Alan N., "Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway" in PLoS One, 10, no. 8 (2015),
https://doi.org/10.1371/journal.pone.0135463 . .

TY  - JOUR
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Sefer, Dijana
AU  - Mitrović-Ajtić, Olivera
AU  - Čokić, Vladan
AU  - Milić, Nataša
PY  - 2015
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/615
AB  - ObjectivesStandard risk stratification for overall survival (OS) in patients with essential thrombocythemia (ET) is based on advanced age and history of thrombotic events. Recently, International Prognostic Score for ET (IPSET) incorporated also leukocytosis in prognostic model. The aim of this study was to establish additional risk factors for OS in ET patients. MethodsAfter the median follow-up of 7yr, in 244 consecutive ET patients, 32 deaths were documented (13.2%). The 5- and 10-yr OS was 95.9% and 79.7%, respectively. Considered additional risk factors at diagnosis of ET were the presence of arterial hypertension, diabetes, hyperlipidemia, and smoking attitude. ResultsThe main cause of death in 75% of patients was cardiovascular (CV) comorbidity. Patients with CV risk factors had increased risk of death (HR=2.33). Cox regression model identified age, leukocytosis, presence of CV risk factors, and previous thrombosis as unfavorable predictors of survival. Based on these parameters, four risk groups were defined, with significantly different survivals (P lt 0.001). Improved prognostic model displayed a better hazard ratio profile compared to the standard risk stratification and IPSET. ConclusionThe addition of CV risk factors allows better prognostic assessment by delineating the intermediate-risk category and improved identification of the high-risk patients.
PB  - Wiley-Blackwell, Hoboken
T2  - European Journal of Haematology
T1  - Predictors of survival and cause of death in patients with essential thrombocythemia
EP  - 466
IS  - 5
SP  - 461
VL  - 95
DO  - 10.1111/ejh.12517
ER  - 

@article{
author = "Leković, Danijela and Gotić, Mirjana and Sefer, Dijana and Mitrović-Ajtić, Olivera and Čokić, Vladan and Milić, Nataša",
year = "2015",
abstract = "ObjectivesStandard risk stratification for overall survival (OS) in patients with essential thrombocythemia (ET) is based on advanced age and history of thrombotic events. Recently, International Prognostic Score for ET (IPSET) incorporated also leukocytosis in prognostic model. The aim of this study was to establish additional risk factors for OS in ET patients. MethodsAfter the median follow-up of 7yr, in 244 consecutive ET patients, 32 deaths were documented (13.2%). The 5- and 10-yr OS was 95.9% and 79.7%, respectively. Considered additional risk factors at diagnosis of ET were the presence of arterial hypertension, diabetes, hyperlipidemia, and smoking attitude. ResultsThe main cause of death in 75% of patients was cardiovascular (CV) comorbidity. Patients with CV risk factors had increased risk of death (HR=2.33). Cox regression model identified age, leukocytosis, presence of CV risk factors, and previous thrombosis as unfavorable predictors of survival. Based on these parameters, four risk groups were defined, with significantly different survivals (P lt 0.001). Improved prognostic model displayed a better hazard ratio profile compared to the standard risk stratification and IPSET. ConclusionThe addition of CV risk factors allows better prognostic assessment by delineating the intermediate-risk category and improved identification of the high-risk patients.",
publisher = "Wiley-Blackwell, Hoboken",
journal = "European Journal of Haematology",
title = "Predictors of survival and cause of death in patients with essential thrombocythemia",
pages = "466-461",
number = "5",
volume = "95",
doi = "10.1111/ejh.12517"
}

Leković, D., Gotić, M., Sefer, D., Mitrović-Ajtić, O., Čokić, V.,& Milić, N.. (2015). Predictors of survival and cause of death in patients with essential thrombocythemia. in European Journal of Haematology
Wiley-Blackwell, Hoboken., 95(5), 461-466.
https://doi.org/10.1111/ejh.12517

Leković D, Gotić M, Sefer D, Mitrović-Ajtić O, Čokić V, Milić N. Predictors of survival and cause of death in patients with essential thrombocythemia. in European Journal of Haematology. 2015;95(5):461-466.
doi:10.1111/ejh.12517 .

Leković, Danijela, Gotić, Mirjana, Sefer, Dijana, Mitrović-Ajtić, Olivera, Čokić, Vladan, Milić, Nataša, "Predictors of survival and cause of death in patients with essential thrombocythemia" in European Journal of Haematology, 95, no. 5 (2015):461-466,
https://doi.org/10.1111/ejh.12517 . .

TY  - CONF
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Sefer, Dijana
AU  - Mitrović-Ajtić, Olivera
AU  - Čokić, Vladan
AU  - Milić, Nataša
PY  - 2015
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/668
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Predictors of survival in patients with essential thrombocythemia
EP  - 101
SP  - 100
VL  - 100
UR  - https://hdl.handle.net/21.15107/rcub_rimi_668
ER  - 

@conference{
author = "Leković, Danijela and Gotić, Mirjana and Sefer, Dijana and Mitrović-Ajtić, Olivera and Čokić, Vladan and Milić, Nataša",
year = "2015",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Predictors of survival in patients with essential thrombocythemia",
pages = "101-100",
volume = "100",
url = "https://hdl.handle.net/21.15107/rcub_rimi_668"
}

Leković, D., Gotić, M., Sefer, D., Mitrović-Ajtić, O., Čokić, V.,& Milić, N.. (2015). Predictors of survival in patients with essential thrombocythemia. in Haematologica
Ferrata Storti Foundation, Pavia., 100, 100-101.
https://hdl.handle.net/21.15107/rcub_rimi_668

Leković D, Gotić M, Sefer D, Mitrović-Ajtić O, Čokić V, Milić N. Predictors of survival in patients with essential thrombocythemia. in Haematologica. 2015;100:100-101.
https://hdl.handle.net/21.15107/rcub_rimi_668 .

Leković, Danijela, Gotić, Mirjana, Sefer, Dijana, Mitrović-Ajtić, Olivera, Čokić, Vladan, Milić, Nataša, "Predictors of survival in patients with essential thrombocythemia" in Haematologica, 100 (2015):100-101,
https://hdl.handle.net/21.15107/rcub_rimi_668 .

TY  - CONF
AU  - Subotički, Tijana
AU  - Beleslin-Čokić, Bojana
AU  - Mitrović, Olivera
AU  - Diklić, Miloš
AU  - Marković, Dragana
AU  - Leković, Danijela
AU  - Sefer, Dijana
AU  - Gotić, Mirjana
AU  - Čokić, Vladan
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/544
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Hypoxic and non-hypoxic proangiogenic stimuli in myeloproliferative neoplasms
EP  - 661
SP  - 661
VL  - 99
UR  - https://hdl.handle.net/21.15107/rcub_rimi_544
ER  - 

@conference{
author = "Subotički, Tijana and Beleslin-Čokić, Bojana and Mitrović, Olivera and Diklić, Miloš and Marković, Dragana and Leković, Danijela and Sefer, Dijana and Gotić, Mirjana and Čokić, Vladan",
year = "2014",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Hypoxic and non-hypoxic proangiogenic stimuli in myeloproliferative neoplasms",
pages = "661-661",
volume = "99",
url = "https://hdl.handle.net/21.15107/rcub_rimi_544"
}

Subotički, T., Beleslin-Čokić, B., Mitrović, O., Diklić, M., Marković, D., Leković, D., Sefer, D., Gotić, M.,& Čokić, V.. (2014). Hypoxic and non-hypoxic proangiogenic stimuli in myeloproliferative neoplasms. in Haematologica
Ferrata Storti Foundation, Pavia., 99, 661-661.
https://hdl.handle.net/21.15107/rcub_rimi_544

Subotički T, Beleslin-Čokić B, Mitrović O, Diklić M, Marković D, Leković D, Sefer D, Gotić M, Čokić V. Hypoxic and non-hypoxic proangiogenic stimuli in myeloproliferative neoplasms. in Haematologica. 2014;99:661-661.
https://hdl.handle.net/21.15107/rcub_rimi_544 .

Subotički, Tijana, Beleslin-Čokić, Bojana, Mitrović, Olivera, Diklić, Miloš, Marković, Dragana, Leković, Danijela, Sefer, Dijana, Gotić, Mirjana, Čokić, Vladan, "Hypoxic and non-hypoxic proangiogenic stimuli in myeloproliferative neoplasms" in Haematologica, 99 (2014):661-661,
https://hdl.handle.net/21.15107/rcub_rimi_544 .

TY  - JOUR
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Peruničić-Jovanović, Maja
AU  - Vidović, Ana
AU  - Bogdanović, Andrija
AU  - Janković, Gradimir
AU  - Čokić, Vladan
AU  - Milić, Nataša
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/540
AB  - The widely used current International Prognostic Scoring System (IPSS) for primary myelofibrosis (PMF) is based on clinical parameters. The objective of this study was to identify additional prognostic factors at the time of diagnosis, which could have an impact on the future treatment of patients with PMF. We conducted a study of 131 consecutive PMF patients with median follow-up of 44 months. Data on baseline demographics, clinical and laboratory parameters, IPSS, grade of bone marrow fibrosis (MF), as well as influence of concomitant comorbidities were analyzed in terms of survival. Comorbidity was assessed using the Adult Comorbidity Evaluation-27 (ACE-27) score and the hematopoietic cell transplantation comorbidity index. An improved prognostic model of survival was obtained by deploying the MF and ACE-27 to the IPSS. A multivariable regression analyses confirmed the statistical significance of IPSS (P  lt  0.001, HR 3.754, 95 % CI 2.130-6.615), MF  gt  1 (P = 0.001, HR 2.694, 95 % CI 1.466-4.951) and ACE-27 (P  lt  0.001, HR 4.141, 95 % CI 2.322-7.386) in predicting the survival of patients with PMF. When the IPSS was modified with MF and ACE-27, the final prognostic model for overall survival was stratified as low (score 0-1), intermediate (score 2-3) and high risk (score 4-6) with median survival of not reached, 115 and 22 months, respectively (P  lt  0.001). Our findings indicate that the combination of histological changes, comorbidity assessment and clinical parameters at the time of diagnosis allows better discrimination of patients in survival prognostic groups and helps to identify high-risk patients for a poor outcome.
PB  - Humana Press Inc, Totowa
T2  - Medical Oncology
T1  - Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis
IS  - 3
VL  - 31
DO  - 10.1007/s12032-014-0869-8
ER  - 

@article{
author = "Leković, Danijela and Gotić, Mirjana and Peruničić-Jovanović, Maja and Vidović, Ana and Bogdanović, Andrija and Janković, Gradimir and Čokić, Vladan and Milić, Nataša",
year = "2014",
abstract = "The widely used current International Prognostic Scoring System (IPSS) for primary myelofibrosis (PMF) is based on clinical parameters. The objective of this study was to identify additional prognostic factors at the time of diagnosis, which could have an impact on the future treatment of patients with PMF. We conducted a study of 131 consecutive PMF patients with median follow-up of 44 months. Data on baseline demographics, clinical and laboratory parameters, IPSS, grade of bone marrow fibrosis (MF), as well as influence of concomitant comorbidities were analyzed in terms of survival. Comorbidity was assessed using the Adult Comorbidity Evaluation-27 (ACE-27) score and the hematopoietic cell transplantation comorbidity index. An improved prognostic model of survival was obtained by deploying the MF and ACE-27 to the IPSS. A multivariable regression analyses confirmed the statistical significance of IPSS (P  lt  0.001, HR 3.754, 95 % CI 2.130-6.615), MF  gt  1 (P = 0.001, HR 2.694, 95 % CI 1.466-4.951) and ACE-27 (P  lt  0.001, HR 4.141, 95 % CI 2.322-7.386) in predicting the survival of patients with PMF. When the IPSS was modified with MF and ACE-27, the final prognostic model for overall survival was stratified as low (score 0-1), intermediate (score 2-3) and high risk (score 4-6) with median survival of not reached, 115 and 22 months, respectively (P  lt  0.001). Our findings indicate that the combination of histological changes, comorbidity assessment and clinical parameters at the time of diagnosis allows better discrimination of patients in survival prognostic groups and helps to identify high-risk patients for a poor outcome.",
publisher = "Humana Press Inc, Totowa",
journal = "Medical Oncology",
title = "Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis",
number = "3",
volume = "31",
doi = "10.1007/s12032-014-0869-8"
}

Leković, D., Gotić, M., Peruničić-Jovanović, M., Vidović, A., Bogdanović, A., Janković, G., Čokić, V.,& Milić, N.. (2014). Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. in Medical Oncology
Humana Press Inc, Totowa., 31(3).
https://doi.org/10.1007/s12032-014-0869-8

Leković D, Gotić M, Peruničić-Jovanović M, Vidović A, Bogdanović A, Janković G, Čokić V, Milić N. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. in Medical Oncology. 2014;31(3).
doi:10.1007/s12032-014-0869-8 .

Leković, Danijela, Gotić, Mirjana, Peruničić-Jovanović, Maja, Vidović, Ana, Bogdanović, Andrija, Janković, Gradimir, Čokić, Vladan, Milić, Nataša, "Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis" in Medical Oncology, 31, no. 3 (2014),
https://doi.org/10.1007/s12032-014-0869-8 . .

TY  - JOUR
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Milić, Nataša
AU  - Miljić, Predrag
AU  - Mitrović, Mirjana
AU  - Čokić, Vladan
AU  - Elezović, Ivo
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/550
AB  - The current widely accepted stratification defined by age and previous thrombosis in patients with essential thrombocythemia (ET) probably deserves deeper analysis. The aim of our study was to identify additional factors at the time of diagnosis, which have an impact on the thrombosis prediction. We conducted a study of 244 consecutive ET patients with median follow-up of 83 months. We analyzed the influence of age, gender, laboratory parameters, history of previous thrombosis, spleen size, JAK2 mutation as well as cardiovascular (CV) risk factors including arterial hypertension, diabetes, active tobacco use and hyperlipidemia in the terms of thrombosis. The most important predictors of thrombosis in multivariate Cox regression model were the presence of CV risk factors (p = 0.004) and previous thrombosis (p = 0.038). Accordingly, we assigned risk scores based on multivariable analysis-derived hazard ratios (HR) to the presence of 1 CV risk factor (HR = 3.5; 1 point),  gt 1 CV risk factors (HR = 8.3; 2 points) and previous thrombosis (HR = 2.0; 1 point). A final three-tiered prognostic model for thrombosis prediction was developed as low (score 0), intermediate (score 1 or 2) and high risk (score 3) (p  lt  0.001). The hazard of thrombosis was 3.8 % in low-risk group, 16.7 % in the intermediate-risk group and 60 % in the high-risk group (p  lt  0.001). Patients with thrombotic complications during the follow-up had a significantly shorter survival (p = 0.018). The new score based on CV risk factors and previous thrombotic events allows a better patient selection within prognostic-risk groups and improved identification of the high-risk patients for thrombosis.
PB  - Humana Press Inc, Totowa
T2  - Medical Oncology
T1  - The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia
IS  - 10
VL  - 31
DO  - 10.1007/s12032-014-0231-1
ER  - 

@article{
author = "Leković, Danijela and Gotić, Mirjana and Milić, Nataša and Miljić, Predrag and Mitrović, Mirjana and Čokić, Vladan and Elezović, Ivo",
year = "2014",
abstract = "The current widely accepted stratification defined by age and previous thrombosis in patients with essential thrombocythemia (ET) probably deserves deeper analysis. The aim of our study was to identify additional factors at the time of diagnosis, which have an impact on the thrombosis prediction. We conducted a study of 244 consecutive ET patients with median follow-up of 83 months. We analyzed the influence of age, gender, laboratory parameters, history of previous thrombosis, spleen size, JAK2 mutation as well as cardiovascular (CV) risk factors including arterial hypertension, diabetes, active tobacco use and hyperlipidemia in the terms of thrombosis. The most important predictors of thrombosis in multivariate Cox regression model were the presence of CV risk factors (p = 0.004) and previous thrombosis (p = 0.038). Accordingly, we assigned risk scores based on multivariable analysis-derived hazard ratios (HR) to the presence of 1 CV risk factor (HR = 3.5; 1 point),  gt 1 CV risk factors (HR = 8.3; 2 points) and previous thrombosis (HR = 2.0; 1 point). A final three-tiered prognostic model for thrombosis prediction was developed as low (score 0), intermediate (score 1 or 2) and high risk (score 3) (p  lt  0.001). The hazard of thrombosis was 3.8 % in low-risk group, 16.7 % in the intermediate-risk group and 60 % in the high-risk group (p  lt  0.001). Patients with thrombotic complications during the follow-up had a significantly shorter survival (p = 0.018). The new score based on CV risk factors and previous thrombotic events allows a better patient selection within prognostic-risk groups and improved identification of the high-risk patients for thrombosis.",
publisher = "Humana Press Inc, Totowa",
journal = "Medical Oncology",
title = "The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia",
number = "10",
volume = "31",
doi = "10.1007/s12032-014-0231-1"
}

Leković, D., Gotić, M., Milić, N., Miljić, P., Mitrović, M., Čokić, V.,& Elezović, I.. (2014). The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. in Medical Oncology
Humana Press Inc, Totowa., 31(10).
https://doi.org/10.1007/s12032-014-0231-1

Leković D, Gotić M, Milić N, Miljić P, Mitrović M, Čokić V, Elezović I. The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia. in Medical Oncology. 2014;31(10).
doi:10.1007/s12032-014-0231-1 .

Leković, Danijela, Gotić, Mirjana, Milić, Nataša, Miljić, Predrag, Mitrović, Mirjana, Čokić, Vladan, Elezović, Ivo, "The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia" in Medical Oncology, 31, no. 10 (2014),
https://doi.org/10.1007/s12032-014-0231-1 . .

TY  - CONF
AU  - Leković, Danijela
AU  - Gotić, Mirjana
AU  - Milić, Nataša
AU  - Miljić, Predrag
AU  - Bogdanović, Andrija
AU  - Milošević, V.
AU  - Mitrović, M.
AU  - Čokić, Vladan
AU  - Elezović, Ivo
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/554
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - A prognostic model to predict thrombosis in essential thrombocythemia
EP  - 394
SP  - 394
VL  - 99
UR  - https://hdl.handle.net/21.15107/rcub_rimi_554
ER  - 

@conference{
author = "Leković, Danijela and Gotić, Mirjana and Milić, Nataša and Miljić, Predrag and Bogdanović, Andrija and Milošević, V. and Mitrović, M. and Čokić, Vladan and Elezović, Ivo",
year = "2014",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "A prognostic model to predict thrombosis in essential thrombocythemia",
pages = "394-394",
volume = "99",
url = "https://hdl.handle.net/21.15107/rcub_rimi_554"
}

Leković, D., Gotić, M., Milić, N., Miljić, P., Bogdanović, A., Milošević, V., Mitrović, M., Čokić, V.,& Elezović, I.. (2014). A prognostic model to predict thrombosis in essential thrombocythemia. in Haematologica
Ferrata Storti Foundation, Pavia., 99, 394-394.
https://hdl.handle.net/21.15107/rcub_rimi_554

Leković D, Gotić M, Milić N, Miljić P, Bogdanović A, Milošević V, Mitrović M, Čokić V, Elezović I. A prognostic model to predict thrombosis in essential thrombocythemia. in Haematologica. 2014;99:394-394.
https://hdl.handle.net/21.15107/rcub_rimi_554 .

Leković, Danijela, Gotić, Mirjana, Milić, Nataša, Miljić, Predrag, Bogdanović, Andrija, Milošević, V., Mitrović, M., Čokić, Vladan, Elezović, Ivo, "A prognostic model to predict thrombosis in essential thrombocythemia" in Haematologica, 99 (2014):394-394,
https://hdl.handle.net/21.15107/rcub_rimi_554 .

TY  - CONF
AU  - Marković, Dragana
AU  - Leković, Danijela
AU  - Mitrović, Olivera
AU  - Đikić, Dragoslava
AU  - Beleslin-Čokić, Bojana
AU  - Subotički, Tijana
AU  - Vignjević, Sanja
AU  - Budeč, Mirela
AU  - Gotić, Mirjana
AU  - Čokić, Vladan
PY  - 2013
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/513
PB  - Ferrata Storti Foundation, Pavia
C3  - Haematologica
T1  - Proangiogenetic molecules vegf, hif-1alpha and enos in myeloproliferative neoplasms
EP  - 616
SP  - 615
VL  - 98
UR  - https://hdl.handle.net/21.15107/rcub_rimi_513
ER  - 

@conference{
author = "Marković, Dragana and Leković, Danijela and Mitrović, Olivera and Đikić, Dragoslava and Beleslin-Čokić, Bojana and Subotički, Tijana and Vignjević, Sanja and Budeč, Mirela and Gotić, Mirjana and Čokić, Vladan",
year = "2013",
publisher = "Ferrata Storti Foundation, Pavia",
journal = "Haematologica",
title = "Proangiogenetic molecules vegf, hif-1alpha and enos in myeloproliferative neoplasms",
pages = "616-615",
volume = "98",
url = "https://hdl.handle.net/21.15107/rcub_rimi_513"
}

Marković, D., Leković, D., Mitrović, O., Đikić, D., Beleslin-Čokić, B., Subotički, T., Vignjević, S., Budeč, M., Gotić, M.,& Čokić, V.. (2013). Proangiogenetic molecules vegf, hif-1alpha and enos in myeloproliferative neoplasms. in Haematologica
Ferrata Storti Foundation, Pavia., 98, 615-616.
https://hdl.handle.net/21.15107/rcub_rimi_513

Marković D, Leković D, Mitrović O, Đikić D, Beleslin-Čokić B, Subotički T, Vignjević S, Budeč M, Gotić M, Čokić V. Proangiogenetic molecules vegf, hif-1alpha and enos in myeloproliferative neoplasms. in Haematologica. 2013;98:615-616.
https://hdl.handle.net/21.15107/rcub_rimi_513 .

Marković, Dragana, Leković, Danijela, Mitrović, Olivera, Đikić, Dragoslava, Beleslin-Čokić, Bojana, Subotički, Tijana, Vignjević, Sanja, Budeč, Mirela, Gotić, Mirjana, Čokić, Vladan, "Proangiogenetic molecules vegf, hif-1alpha and enos in myeloproliferative neoplasms" in Haematologica, 98 (2013):615-616,
https://hdl.handle.net/21.15107/rcub_rimi_513 .